



(86) Date de dépôt PCT/PCT Filing Date: 2002/04/05
(87) Date publication PCT/PCT Publication Date: 2002/10/17
(45) Date de délivrance/Issue Date: 2011/06/07
(85) Entrée phase nationale/National Entry: 2003/10/03
(86) N° demande PCT/PCT Application No.: US 2002/010733
(87) N° publication PCT/PCT Publication No.: 2002/080849
(30) Priorité/Priority: 2001/04/06 (US60/282,040)


(51) Cl.Int./Int.Cl. *A61K 48/00* (2006.01),
A61K 38/19 (2006.01), *A61K 45/06* (2006.01),
C07H 21/00 (2006.01), *C12N 15/00* (2006.01),
C12N 15/09 (2006.01), *C12N 15/63* (2006.01),
C12N 15/67 (2006.01), *C12N 15/85* (2006.01),
C12N 15/861 (2006.01)

(72) Inventeurs/Inventors:
WEICHSELBAUM, RALPH R., US;
KUFE, DONALD W., US;
GUPTA, VINAY, US;
MAUCERI, HELEN, US;

...

(73) Propriétaires/Owners:

(54) Titre : INDUCTION CHIMIOThERAPEUTIQUE DE L'ACTIVITE DU PROMOTEUR EGR-1
(54) Title: CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY



(57) Abrégé/Abstract:

The present invention provides for improved therapeutic regimens for treating benign hyperproliferative diseases and cancers. The Egr-1 promoter, long known to be radiation-responsive, has now been shown to be inducible for DNA damaging chemical agents,

(72) **Inventeurs(suite)/Inventors(continued):** PARK, JAMES, US; POSNER, MITCHELL, US

(73) **Propriétaires(suite)/Owners(continued):**UNIVERSITY OF CHICAGO, US; DANA-FARBER CANCER INSTITUTE, US

(74) **Agent:** FETHERSTONHAUGH & CO.

(57) **Abrégé(suite)/Abstract(continued):**

many of which themselves are used in therapies. Thus, the present invention provides for the advantages combination of a DNA damaging chemical and an expression vector containing a therapeutic gene driven by the Egr-1 promoter.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/080849 A3

(51) International Patent Classification⁷: **A61K 48/00**,
C12N 15/00, 15/09, 15/63, 15/85, C07H 21/00

Mitchell [US/US]; 442 W. Wellington # 6W, Chicago, IL
60657 (US).

(21) International Application Number: PCT/US02/10733

(74) Agent: **HIGHLANDER, Steven, L.**; Fulbright & Ja-
worski L.L.P., Suite 2400, 600 Congress Avenue, Austin,
TX 78701 (US).

(22) International Filing Date: 5 April 2002 (05.04.2002)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
60/282,040 6 April 2001 (06.04.2001) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/282,040 (CON)
Filed on 6 April 2001 (06.04.2001)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **UNIVER-
SITY OF CHICAGO** [US/US]; 5640 South Ellis Avenue,
Chicago, IL 60637 (US).

(72) Inventors; and

Published:

(75) Inventors/Applicants (*for US only*): **WEICHSEL-
BAUM, Ralph, R.** [US/US]; 1909 North Burling,
Chicago, IL 60614 (US). **KUFE, Donald, W.** [US/US];
179 Grove Street, Wellesley, MA 02181 (US). **GUPTA,
Vinay** [US/US]; 1637 West Altgeld, Chicago, IL 60637
(US). **MAUCERI, Helen** [US/US]; 2046 Burnham Place,
Wheaton, IL 60187 (US). **PARK, James** [US/US]; 526 E.
32nd ST. Unit # E, Chicago, IL 60616 (US). **POSNER,**

— with international search report

(88) Date of publication of the international search report:
13 February 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY

(57) Abstract: The present invention provides for improved therapeutic regimens for treating benign hyperproliferative diseases and cancers. The Egr-1 promoter, long known to be radiation-responsive, has now been shown to be inducible for DNA damaging chemical agents, many of which themselves are used in therapies. Thus, the present invention provides for the advantages combination of a DNA damaging chemical and an expression vector containing a therapeutic gene driven by the Egr-1 promoter.



WO 02/080849 A3

DESCRIPTION

CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to the fields of molecular biology and cancer therapy. More particularly, it concerns use of the DNA damaging chemicals to induce expression of the Egr-1 promoter. This permits tissue specific expression of therapeutic genes which, in combination with the DNA damaging chemicals, provide therapy to patients suffering from cancer.

2. Description of Related Art

Certain cancer treatment methods, including radiotherapy and chemotherapy, involve damaging the DNA of the cancer cell. The cellular response to normal DNA damage includes activation of DNA repair, cell cycle arrest and lethality (Hall, 1988). For example, the induction of DNA double-strand breaks results in lethal chromosomal aberrations that include deletions, dicentrics, rings, and anaphase bridges (Hall, 1994).

Another approach to treating cancers is gene therapy. This involves the transfer of a foreign gene into a cancer cell, often a tumor suppressor or inducer of apoptosis, under conditions suitable for expression of the gene. Once expressed, the gene product confers a beneficial effect on the tumor cell by either slowing its growth, inhibiting its metastatic potential, or killing it outright.

Combining one or more of these methods is a powerful tool as heterogeneity in many tumors makes mono-therapies far less effective than combinations. However, radio-, chemo- and gene therapy all have the potential for toxic effects. Thus, being able to reduce toxicity, for example, by reducing the amount of radiation/drug/vector administered, is highly advantageous.

For example, tumor necrosis factor-alpha (TNF- α), which has antitumor properties, has been studied as a systemic gene-therapy treatment for cancer in phase 1 studies, but toxicity has limited the therapeutic index of this cytokine (Spriggs *et al.*, 1988; Demetri *et al.*, 1989). Also, combinations of systemic TNF- α and chemotherapy have been investigated in a few clinical trials with limited success (Nakamoto *et al.*, 2000).

On the other hand, chemotherapeutic agents such as cisplatin and other platinum analogues are currently employed in the treatment of several cancers including head and neck, esophageal, lung, testis, ovarian, and bladder cancers. Additionally, cisplatin is used concurrently with irradiation (IR) as a radiosensitizer. In spite of the relative efficacy of cisplatin, tumor-resistance has limited the role of cisplatin in curative cancer chemotherapy (Johnson and Stevenson, 2001). Tumor-derived mechanisms of cisplatin-resistance include an increase in DNA repair of cisplatin adducts in tumor cells, an increase in glutathione, which inhibits free-radical formation and subsequent DNA damage, and a relative decrease in uptake of cisplatin by resistant cells (Kartalou and Essigmann, 2001). The combination of cisplatin with other chemotherapeutic agents, especially 5-FU and VP-16, has increased the therapeutic index of both agents in some human tumors (Kucuk *et al.*, 2000), but other strategies are needed to increase the efficacy of cisplatin.

Thus, there is a need in the art to improve both gene-therapeutic as well as chemotherapeutic treatment regimens. Therapies that combine the benefits of different treatment regimens, at the same time reducing the associated side-effects, are desired.

SUMMARY OF THE INVENTION

The present invention overcomes the deficiencies in the art and provides methods that enhance the therapeutic utility of gene-therapy as well chemotherapy. A transcriptional targeting strategy has been developed wherein inducible expression vectors that encode for therapeutic genes are induced by chemotherapeutic agents. The chemotherapeutic agents specifically target inducible promoters of the expression vector to provide targeted therapy. The therapeutic methods provided are especially effective in treating tumors.

Therefore, in accordance with the present invention, there are provided methods for expressing a protein of interest comprising (a) providing an expression construct comprising a nucleic acid segment encoding the protein of interest, the nucleic acid segment being positioned under the control of an Egr-1 promoter; (b) transferring the expression construct into a cell; (c)

28778-148

contacting the cell with at least one free radical-inducing DNA damaging compound, whereby the DNA damaging compound induces expression of the protein of interest from the Egr-1 promoter.

The free radical-inducing DNA damaging compound may be a platinum compound such as cisplatin, a nitrogen mustard, cytoxan, cyclophosphamide, mitomycin c, adriamycin, iphosphamide, bleomycin, doxorubicin, procarbazine, actinomycin, chlorambucil, carboplatinum, busulfan, bcnu, ccnu, hexamethylmelamineoxaliplatin, epirubicin, daunorubicin, camptothecin, or mitoxantrone. Step (c) may comprise contacting the cell with at least a second free-radical inducing DNA damaging compound. The method may further comprise contacting the cell with a cancer chemotherapeutic compound or ionizing radiation. The cell may be a cancer cell, for example, a lung cancer cell, prostate cancer cell, ovarian cancer cell, testicular cancer cell, brain cancer cell, skin cancer cell, colon cancer cell, gastric cancer cell, esophageal cancer cell, tracheal cancer cell, head & neck cancer cell, pancreatic cancer cell, liver cancer cell, breast cancer cell, ovarian cancer cell, lymphoid cancer cell, leukemia cell, cervical cancer cell, or vulvar cancer cell.

The expression vector may further comprise an origin of replication, a selectable marker, or a polyadenylation signal operable linked to the nucleic segment. The expression vector may be plasmid or a viral vector, for example, an adenoviral vector, an adeno-associated viral vector, a retroviral vector, a lentiviral vector, a vaccinia viral vector, or a herpesviral vector. The viral vector may lack one or more viral genes, thus rendering the viral vector non-replicative. The cell may be located in an organism, for example, a human.

The protein of interest may be a tumor suppressor, an inducer of apoptosis, an enzyme, a toxin, a cytokine, or any other protein with antitumor activity. Examples of tumor suppressors are Rb, p16, p53, PTEN, MDA7 or BRCA1 or BRCA2. Examples of inducers of apoptosis are Bax, Bad, Bik, AdE1B, Bim, Bcl-X_s, Bak, TRAIL, Harakiri or Bid. Examples of enzymes are thymidine kinase, cytosine deaminase, hypoxanthine guanine phosphoribosyl transferase. Examples of toxin are pseudomonas exotoxin, diptheria toxin, cholera toxin, pertussis toxin A subunit, enterotoxin A, or ricin A chain. Other molecules with antitumor activity include interleukins (IL) and cytokines exemplified by, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, β -interferon, α -interferon, γ -interferon, angiostatin, thrombospondin, endostatin, METH-1, METH-2, GM-CSF, G-CSF, M-CSF and tumor necrosis factors (TNF) such as TNF- α and TNF- β . The skilled artisan will recognize that the invention is

not limited by any particular protein of interest, such as those disclosed above, as long as the protein has an antitumor effect.

In another embodiment, the invention provides methods for treating cancer in a subject comprising (a) providing an expression construct comprising a nucleic acid segment encoding a cancer therapeutic protein, the nucleic acid segment being positioned under the control of an Egr-1 promoter; and (b) administering the expression construct to the subject in combination with a free radical-inducing DNA damaging compound, whereby the DNA damaging compound induces expression of the cancer therapeutic protein from the Egr-1 promoter, thereby treating the cancer in the subject. The expression construct may be delivered local or regional to a tumor located in the subject, delivered systemically, or delivered via intratumoral injection or by direct injection into tumor vasculature.

The DNA damaging compound may be administered prior to administering the expression vector, after administering the expression vector, or at the same time as the expression vector. The expression vector and or DNA damaging agent may be administered at least twice. The cancer therapeutic protein may be a tumor suppressor, an inducer of apoptosis, an enzyme, a toxin, a cytokine, or any protein with anti-tumor activity.

In yet another embodiment, there are provided methods for inhibiting tumor cell growth in a subject comprising (a) providing an expression construct comprising a nucleic acid segment encoding a cancer therapeutic protein, the nucleic acid segment being positioned under the control of an Egr-1 promoter; and (b) administering the expression construct to the subject in combination with a free radical-inducing DNA damaging compound, whereby the DNA damaging compound induces expression of the cancer therapeutic protein from the Egr-1 promoter, thereby inhibiting tumor cell growth in the subject. In one such embodiment, the cancer therapeutic protein is TNF- α . In another such embodiment, the free radical-inducing DNA damaging compound is cisplatin.

In still yet another embodiment, there are provided methods for killing a tumor cell in a subject comprising (a) providing an expression construct comprising a nucleic acid segment encoding a cancer therapeutic protein, the nucleic acid segment being positioned under the control of an Egr-1 promoter; and (b) administering the expression construct to the subject in combination with a free radical-inducing DNA damaging compound, whereby the DNA damaging compound induces expression of the cancer therapeutic protein from the Egr-1 promoter, thereby killing the tumor cell in the subject.

31802-1

In still a further embodiment, there are provided methods for inhibiting tumor cell metastasis in a subject comprising (a) providing an expression construct comprising a nucleic acid segment encoding a cancer therapeutic protein, the nucleic acid segment being positioned under the control of an Egr-1 promoter; and (b) administering the expression construct to the subject in combination with a free radical-inducing DNA damaging compound, whereby the DNA damaging compound induces expression of the cancer therapeutic protein from the Egr-1 promoter, thereby inhibiting tumor cell metastasis in the subject.

In even a further embodiment, there are provided methods for reducing tumor burden in a subject comprising (a) providing an expression construct comprising a nucleic acid segment encoding a cancer therapeutic protein, the nucleic acid segment being positioned under the control of an Egr-1 promoter; and (b) administering the expression construct to the subject in combination with a free radical-inducing DNA damaging compound, whereby the DNA damaging compound induces expression of the cancer therapeutic protein from the Egr-1 promoter, thereby reducing tumor burden in the subject.

In an additional embodiment, there are provided methods for rendering an inoperable tumor operable comprising (a) providing an expression construct comprising a nucleic acid segment encoding a cancer therapeutic protein, the nucleic acid segment being positioned under the control of an Egr-1 promoter; and (b) administering the expression construct to the subject in combination with a free radical-inducing DNA damaging compound, whereby the DNA damaging compound induces expression of the cancer therapeutic protein from the Egr-1 promoter, thereby reducing the size or shape of the tumor and rendering susceptible to resection.

31802-1

In another embodiment, there is provided a method for expressing a protein of interest comprising: (a) providing an expression construct comprising a nucleic acid segment encoding said protein of interest, said nucleic acid segment being
5 positioned under the control of an Egr-1 promoter; (b) transferring said expression construct into a cell; and (c) contacting said cell with a DNA damaging chemotherapeutic agent that induces said Egr-1 promoter, whereby said chemotherapeutic agent induces expression of said protein of interest from said
10 Egr-1 promoter.

In yet another embodiment, there is provided a use, for inhibiting tumor cell growth in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent that induces an Egr-1 promoter, wherein the expression
15 construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of the Egr-1 promoter; and said chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

20 In yet another embodiment, there is provided a use, for treating cancer in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent, wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid
25 segment being positioned under the control of an early growth response factor 1 (Egr-1) promoter; and said chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

In yet another embodiment, there is provided a use,
30 for killing a tumor cell in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic

31802-1

agent, wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an Egr-1 promoter; and said chemotherapeutic agent induces
5 expression of said cancer therapeutic protein from said Egr-1 promoter.

In yet another embodiment, there is provided a use, for inhibiting tumor cell metastasis in a subject, of an expression construct in combination with a DNA damaging
10 chemotherapeutic agent, wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early response growth factor 1 (Egr-1) promoter; and said chemotherapeutic agent induces expression of said
15 cancer therapeutic protein from said Egr-1 promoter.

In yet another embodiment, there is provided a use, for reducing tumor burden in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic compound, wherein the expression construct comprises a nucleic
20 acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early response growth factor 1 (Egr-1) promoter; and said DNA damaging compound induces expression of said cancer therapeutic protein from said Egr-1 promoter.

25 In yet another embodiment, there is provided a use, in the manufacture of a medicament for rendering a tumor operable, of an expression construct in combination with a DNA damaging chemotherapeutic agent, wherein the expression construct comprises a nucleic acid segment encoding a cancer
30 therapeutic protein, said nucleic acid segment being positioned under the control of an early response growth factor 1 (Egr-1)

31802-1

promoter; and wherein said chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

5 In yet another embodiment, there is provided an in vitro or ex vivo method for expressing a protein of interest comprising: (a) providing a cell comprising an expression construct comprising a nucleic acid segment encoding said protein of interest, said nucleic acid segment being positioned under the control of an early response growth factor 1 (Egr-1)
10 promoter; and (b) contacting said cell with a DNA damaging chemotherapeutic agent which induces expression of said protein of interest from said Egr-1 promoter.

In yet another embodiment, there is provided an expression vector in combination with at least one DNA damaging
15 chemotherapeutic agent for use in therapy, wherein the expression vector comprises a nucleic acid segment encoding a protein of interest, the nucleic acid segment being positioned under the control of an early growth response factor 1 (Egr-1) promoter, wherein said chemotherapeutic agent induces
20 expression of said protein of interest from said Egr-1 promoter in a cell.

As used herein the specification, "a" or "an" may mean one or more. As used herein in the claim(s), when used in conjunction with the word "comprising", the words "a" or "an"
25 may mean one or more than one. As used herein "another" may mean at least a second or more.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the
30 detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by

31802-1

way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1. Chemoinduction in Seg-1. Fractional tumor volume is measured as a function of time and treatment (Seg-1 = esophageal carcinoma cell line; UTC = untreated control; Ad.Egr.TNF = adenovirus encoded tumor necrosis factor under control of the Egr-1 promoter; plat = cisplatin at 4 mg/kg; A.TNF/plat = Ad.Egr.TNF + plat).

FIG. 2. TNF expression with chemoinduction. TNF production in picograms per ml as a function of time (5 days or 10 days) and treatment (utc = untreated control; Ad.TNF = adenovirus encoded tumor necrosis factor under control of the Egr-1 promoter; Platnm = cisplatin; TNF/Pltm = Ad.TNF + Platnm).

FIG. 3. TNF induction with 4 mg/kg platinum. TNF production in picograms per mg protein as a function of time (5 days or 10 days) and treatment (Ad.TNF = adenovirus encoded tumor necrosis factor under control of the Egr-1 promoter; TNF/Pltm = Ad.TNF + cisplatin).

FIG. 4. Dose response of platinum in Ad.Egr.TNF-treated Seg-1. Fractional tumor volume is measured as a function of time and treatment (Seg-1 = esophageal carcinoma cell line; pbs = phosphate buffered saline; Ad.TNF = adenovirus encoded tumor necrosis factor under control of the Egr-1 promoter; Plat1 = cisplatin at 1 mg/kg; Plat3 = cisplatin at 3 mg/kg; Plat6 = cisplatin at 6 mg/kg; Plat1/TNF = cisplatin at 1 mg/kg + Ad.TNF; Plat3/TNF = cisplatin at 3 mg/kg + Ad.TNF; Plat6/TNF = cisplatin at 6 mg/kg + Ad.TNF).

FIGS. 5A & 5B. *In vitro* measurement of TNF- α protein. TNF- α production by Ad.Egr.TNF.11D-infected cells exposed to IR (5 Gy) or cisplatin (5 μ M) was measured using ELISA. Significant levels of TNF- α protein were detected at 24, 48 and 72 hrs following exposure to Ad.Egr.TNF.11D + IR ($P < 0.001$) and Ad.Egr.TNF.11D + cisplatin ($P < 0.001$) compared with vector alone in Seg-1 cultures (FIG. 5A) and PROb cultures (FIG. 5B). Data are reported as mean $\pm$ SEM.

FIGS. 6A & 6B. *In vitro* reporter assays. Luciferase reporter constructs were used to evaluate induction of the Egr-1 promoter by IR or cisplatin. Minimal luciferase activity was detectable following transfection with either the pGL3 (negative control) or the pGL3 660

plasmid (minimal Egr-1 promoter) constructs. FIG. 6A. In Seg-1 cells, a 2.4-fold increase ($P=0.005$) in relative luciferase activity was observed following exposure to IR (20 Gy) and a 2.0-fold increase ($P=0.005$) following exposure to cisplatin (50 μ M). FIG. 6B. In PROb cells, a 4.2-fold increase ($P=0.004$) in relative luciferase activity was observed following exposure to IR (20 Gy) and a 3.6-fold increase ($P=0.01$) following exposure to cisplatin (50 μ M). Data are reported as mean $\pm$ SEM.

FIGS. 7A & 7B. *In vivo* measurement of TNF- α protein. TNF- α production by Ad.Egr.TNF.11D-injected xenografts was measured by ELISA. A significant increase in intratumoral TNF- α protein concentration was observed following combined treatment with Ad.Egr.TNF.11D + cisplatin compared with treatment with Ad.Egr.TNF.11D vector alone in Seg-1 (FIG. 7A) (3.5-fold increase; $P<0.05$) and PROb (FIG. 7B) xenografts (2.7-fold; $P<0.001$). Data are reported as mean $\pm$ SEM.

FIGS. 8A & 8B. *In vivo* regrowth studies. The effect of combined treatment with Ad.Egr.TNF.11D and cisplatin was evaluated by measuring the volume of xenografts injected with Ad.Null.3511.11D or Ad.Egr.TNF.11D with or without cisplatin. FIG. 8A. In Seg-1 xenografts combined treatment with Ad.Egr.TNF.11D + cisplatin produced significant tumor regression compared with tumors treated with the Ad.Null + cisplatin at days on days 4 ($P=0.045$), 6 ($P<0.005$), 8 ($P<0.002$), 10 ($P<0.001$), 12 ($P<0.004$), and 14 ($P<0.021$). FIG. 8B. In PROb xenografts significant tumor regression was observed in the tumors receiving combined treatment with Ad.Egr.TNF.11D + cisplatin compared with tumors treated Ad.Null + cisplatin at days on days 4 ($P=0.045$), 6 ($P<0.001$), 8 ($P=0.048$), 10 ($P<0.001$), 12 ($P<0.001$), and 14 ($P=0.002$). Data are reported as mean $\pm$ SEM.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The present invention stems in part from the inventors' observation that the Egr-1 promoter, long known to contain radiation-responsive elements, also may be induced by DNA damaging chemicals. This surprising observation provides for a previously unattempted combination therapy for hyperproliferative diseases such as cancer - using an expression construct containing the Egr-1 promoter encoding an antitumor gene such a tumor necrosis factor (TNF) in conjunction with a DNA damaging chemical.

The combined therapeutic effect of the DNA damaging agent and induced expression of the therapeutic gene in cancer cells provides a superior result to use of either agent alone and also allows for using reduced doses of each agent. Being able to reduce any systemic toxicity,

by reducing the amount of radiation and/or drug and/or vector administered, is highly advantageous. The following disclosure provides a detailed description of the foregoing embodiments, as well as variations thereof.

A transcriptional targeting strategy is provided whereby chemotherapeutic agents in conjunction with inducible expression vectors that encode for genes with antitumor effects may be used to effectively treat tumors, where the vectors are induced by the chemotherapeutic agent. Thus, expression constructs comprising the inducible Egr-1 promoter and encoding for any antitumor gene in conjunction with a chemotherapeutic agent that can induce and activate the Egr-1 promoter, via DNA damage or production of ROI's, are provided.

With a selective tumor-targeting vector, a genetic construct that expresses an antitumor gene that is inducible by a chemotherapeutic enhances the effects of the chemotherapeutic as well as the antitumor agent. As both the chemotherapeutic agent and the antitumor gene will generally have different mechanisms of tumor cell killing therefore, cells resistant to one agent may be sensitive to the other. It is also contemplated that such combinations may enhance the local effects of combination chemo-radiation therapy or other adjunct cancer therapies.

A. Egr-1 Promoter

The Egr-1 promoter is defined herein as those 5' regulatory sequences necessary to control the DNA damaging agent-induced transcription of downstream sequences operably connected thereto. The Egr-1 promoter has complex structure which has previously been analyzed in the context of radiation- and H₂O₂-induced gene expression. It contains multiple ETS binding sites (ETS are transcriptional regulatory proteins), three of which exist as parts of two serum response elements (SRE's), SREI and SREII. The SRE's, also known as CArG motifs, are cis-elements that regulate the expression of many growth factor responsive genes. There are a total of six SRE's, each comprising the consensus CC(A+T-rich)6GG sequence.

The present inventors have previously demonstrated that a chimeric genetic construct consisting of the 5' Egr-1 CArG elements ligated to the TNF- α cDNA express high levels of intratumoral TNF- α following IR exposure of cells transduced with this construct. Tumors transduced with the chimeric Egr-TNF construct and treated with IR exhibited increased regression/cures compared with tumors treated with either agent alone, likely due to the intratumoral induction of TNF- α production by IR, and the cytotoxic interaction of TNF- α and IR on the tumor cells and the tumor vasculature (Weichselbaum *et al.*, 2001; Staba *et al.*, 1998). In the present invention, the inventors used cisplatin, a commonly used chemotherapeutic agent that alters intracellular radical oxygen formation and damages DNA, to induce the TNF- α gene

under control of the DNA damage / ROI inducible CArG elements of the Egr-1 promoter. The invention therefore provides the use of agents that cause DNA damage and/or produce ROI to induce Egr-1 and therefore to drive the expression of genes under the control of Egr-1 in expression vectors.

5

B. DNA Damaging Chemicals

The term "DNA damaging chemical" refers to the any drug that induces, either directly or indirectly, damage to a DNA molecule. Of particular interest in the present invention are those drugs that generate free radicals. The following categories of chemicals are believed to effect DNA damage through one or more pathways.

10

I. Alkylating Agents

Alkylating agents are drugs that directly interact with genomic DNA to prevent the cancer cell from proliferating. This category of chemotherapeutic drugs represents agents that affect all phases of the cell cycle, that is, they are not phase-specific. Alkylating agents can be implemented to treat, for example, chronic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, and particular cancers of the breast, lung, and ovary. An alkylating agent, may include, but is not limited to, a nitrogen mustard, an ethylenimine, a methylmelamine, an alkyl sulfonate, a nitrosourea or a triazines.

15

They include but are not limited to: busulfan, chlorambucil, cisplatin, cyclophosphamide (cytoxan), dacarbazine, ifosfamide, mechlorethamine (mustargen), and melphalan. In specific aspects, troglitazone can be used to treat cancer in combination with any one or more of these alkylating agents, some of which are discussed below.

20

i. Nitrogen Mustards

25

A nitrogen mustard may be, but is not limited to, mechlorethamine (HN_2), which is used for Hodgkin's disease and non-Hodgkin's lymphomas; cyclophosphamide and/or ifosfamide, which are used in treating such cancers as acute or chronic lymphocytic leukemias, Hodgkin's disease, non-Hodgkin's lymphomas, multiple myeloma, neuroblastoma, breast, ovary, lung, Wilm's tumor, cervix testis and soft tissue sarcomas; melphalan (L-sarcolysin), which has been used to treat such cancers as multiple myeloma, breast and ovary; and chlorambucil, which has been used to treat diseases such as, for example, chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease and non-Hodgkin's lymphomas.

30

a. Chlorambucil

Chlorambucil (also known as leukeran) is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.

5 Chlorambucil is known chemically as 4-[bis(2-chlorethyl)amino] benzenebutanoic acid.

Chlorambucil is available in tablet form for oral administration. It is rapidly and completely absorbed from the gastrointestinal tract. For example, after a single oral doses of about 0.6 mg/kg to about 1.2 mg/kg, peak plasma chlorambucil levels are reached within one hour and the terminal half-life of the parent drug is estimated at about 1.5 hours. About
10 0.1 mg/kg/day to about 0.2 mg/kg/day or about 3 6 mg/m²/day to about 6 mg/m²/day or alternatively about 0.4 mg/kg may be used for antineoplastic treatment. Chlorambucil is not curative by itself but may produce clinically useful palliation.

b. Cyclophosphamide

15 Cyclophosphamide is 2*H*-1,3,2-Oxazaphosphorin-2-amine, *N,N*-bis(2-chloroethyl)tetrahydro-, 2-oxide, monohydrate; termed Cytosan available from Mead Johnson; and Neosar available from Adria. Cyclophosphamide is prepared by condensing 3-amino-1-propanol with *N,N*-bis(2-chlorethyl) phosphoramidic dichloride [(ClCH₂CH₂)₂N--POCl₂] in dioxane solution under the catalytic influence of triethylamine. The condensation is double,
20 involving both the hydroxyl and the amino groups, thus effecting the cyclization.

Unlike other β-chloroethylamino alkylators, it does not cyclize readily to the active ethyleneimonium form until activated by hepatic enzymes. Thus, the substance is stable in the gastrointestinal tract, tolerated well and effective by the oral and parental routes and does not cause local vesication, necrosis, phlebitis or even pain.

25 Suitable oral doses for adults include, for example, about 1 mg/kg/day to about 5 mg/kg/day (usually in combination), depending upon gastrointestinal tolerance; or about 1 mg/kg/day to about 2 mg/kg/day; intravenous doses include, for example, initially about 40 mg/kg to about 50 mg/kg in divided doses over a period of about 2 days to about 5 days or about 10 mg/kg to about 15 mg/kg about every 7 days to about 10 days or about 3 mg/kg to
30 about 5 mg/kg twice a week or about 1.5 mg/kg/day to about 3 mg/kg/day. In some aspects, a dose of about 250 mg/kg/day may be administered as an antineoplastic. Because of gastrointestinal adverse effects, the intravenous route is preferred for loading. During maintenance, a leukocyte count of about 3000/mm³ to 4000/mm³ usually is desired. The drug also sometimes is administered intramuscularly, by infiltration or into body cavities. It is

available in dosage forms for injection of about 100 mg, about 200 mg and about 500 mg, and tablets of about 25 mg and about 50 mg.

c. Melphalan

Melphalan, also known as alkeran, L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, is a phenylalanine derivative of nitrogen mustard. Melphalan is a bifunctional alkylating agent which is active against selective human neoplastic diseases. It is known chemically as 4-[bis(2-chloroethyl)amino]-L-phenylalanine.

Melphalan is the active L-isomer of the compound and was first synthesized in 1953 by Bergel and Stock; the D-isomer, known as medphalan, is less active against certain animal tumors, and the dose needed to produce effects on chromosomes is larger than that required with the L-isomer. The racemic (DL-) form is known as merphalan or sarcolysin. Melphalan is insoluble in water and has a pK_{a1} of about 2.1. Melphalan is available in tablet form for oral administration and has been used to treat multiple myeloma. Available evidence suggests that about one third to one half of the patients with multiple myeloma show a favorable response to oral administration of the drug.

Melphalan has been used in the treatment of epithelial ovarian carcinoma. One commonly employed regimen for the treatment of ovarian carcinoma has been to administer melphalan at a dose of about 0.2 mg/kg daily for five days as a single course. Courses are repeated about every four to five weeks depending upon hematologic tolerance (Smith and Rutledge, 1975; Young *et al.*, 1978). Alternatively, in certain embodiments, the dose of melphalan used could be as low as about 0.05 mg/kg/day or as high as about 3 mg/kg/day or greater.

ii. Ethylenimenes and Methymelamines

An ethylenimine and/or a methymelamine include, but are not limited to, hexamethylmelamine, used to treat ovary cancer; and thiotepa, which has been used to treat bladder, breast and ovary cancer.

iii. Alkyl Sulfonates

An alkyl sulfonate includes but is not limited to such drugs as busulfan, which has been used to treat chronic granulocytic leukemia. Busulfan (also known as myleran) is a bifunctional alkylating agent. Busulfan is known chemically as 1,4-butanediol dimethanesulfonate. Busulfan is available in tablet form for oral administration, wherein for example, each scored tablet

contains about 2 mg busulfan and the inactive ingredients magnesium stearate and sodium chloride.

Busulfan is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. Although not curative, busulfan reduces the total granulocyte mass, relieves symptoms of the disease, and improves the clinical state of the patient. Approximately 90% of adults with previously untreated chronic myelogenous leukemia will obtain hematologic remission with regression or stabilization of organomegaly following the use of busulfan. Busulfan has been shown to be superior to splenic irradiation with respect to survival times and maintenance of hemoglobin levels, and to be equivalent to irradiation at controlling splenomegaly.

iv. Nitrosoureas

Nitrosoureas, like alkylating agents, inhibit DNA repair proteins. They are used to treat non-Hodgkin's lymphomas, multiple myeloma, malignant melanoma, in addition to brain tumors. A nitrosourea include but is not limited to a carmustine (BCNU), a lomustine (CCNU), a semustine (methyl-CCNU) or a streptozocin. Semustine has been used in such cancers as a primary brain tumor, a stomach or a colon cancer. Streptozocin has been used to treat diseases such as a malignant pancreatic insulinoma or a malignant carcinoid. Streptozocin has been used to treat such cancers as a malignant melanoma, Hodgkin's disease and soft tissue sarcomas.

a. Carmustine

Carmustine (sterile carmustine) is one of the nitrosoureas used in the treatment of certain neoplastic diseases. It is 1,3 bis (2-chloroethyl)-1-nitrosourea. It is lyophilized pale yellow flakes or congealed mass with a molecular weight of 214.06. It is highly soluble in alcohol and lipids, and poorly soluble in water. Carmustine is administered by intravenous infusion after reconstitution as recommended

Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in brain tumors such as glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. Also it has been used in combination with prednisone to treat multiple myeloma. Carmustine has been used in treating such cancers as a multiple myeloma or a malignant

melanoma. Carmustine has proved useful, in the treatment of Hodgkin's Disease and in non-Hodgkin's lymphomas, as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

5 Sterile carmustine is commonly available in 100 mg single dose vials of lyophilized material. The recommended dose of carmustine as a single agent in previously untreated patients is about 150 mg/m² to about 200 mg/m² intravenously every 6 weeks. This may be given as a single dose or divided into daily injections such as about 75 mg/m² to about 100 mg/m² on 2 successive days. When carmustine is used in combination with other myelosuppressive drugs 10 or in patients in whom bone marrow reserve is depleted, the doses should be adjusted accordingly. Doses subsequent to the initial dose should be adjusted according to the hematologic response of the patient to the preceding dose. It is of course understood that other doses may be used in the present invention, for example about 10 mg/m², about 20 mg/m², about 30 mg/m², about 40 mg/m², about 50 mg/m², about 60 mg/m², about 70 mg/m², about 80 mg/m², 15 about 90 mg/m² to about 100 mg/m².

b. Lomustine

Lomustine is one of the nitrosoureas used in the treatment of certain neoplastic diseases. It is 1-(2-chloro-ethyl)-3-cyclohexyl-1 nitrosourea. It is a yellow powder with the empirical 20 formula of C₉H₁₆ClN₃O₂ and a molecular weight of 233.71. Lomustine is soluble in 10% ethanol (about 0.05 mg/mL) and in absolute alcohol (about 70 mg/mL). Lomustine is relatively insoluble in water (less than about 0.05 mg/mL). It is relatively unionized at a physiological pH. Inactive ingredients in lomustine capsules are: magnesium stearate and mannitol.

25 Although it is generally agreed that lomustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamylation of amino acids in proteins.

Lomustine may be given orally. Following oral administration of radioactive lomustine at doses ranging from about 30 mg/m² to 100 mg/m², about half of the radioactivity given was excreted in the form of degradation products within 24 hours. The serum half-life of the 30 metabolites ranges from about 16 hours to about 2 days. Tissue levels are comparable to plasma levels at 15 minutes after intravenous administration.

Lomustine has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in both primary and metastatic brain tumors, in patients who have already received appropriate

surgical and/or radiotherapeutic procedures. Lomustine has been used to treat such cancers as small-cell lung cancer. It has also proved effective in secondary therapy against Hodgkin's Disease in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

5 The recommended dose of lomustine in adults and children as a single agent in previously untreated patients is about 130 mg/m^2 as a single oral dose every 6 weeks. In individuals with compromised bone marrow function, the dose should be reduced to about 100 mg/m^2 every 6 weeks. When lomustine is used in combination with other myelosuppressive drugs, the doses should be adjusted accordingly. It is understood that other doses may be used
10 for example, about 20 mg/m^2 , about 30 mg/m^2 , about 40 mg/m^2 , about 50 mg/m^2 , about 60 mg/m^2 , about 70 mg/m^2 , about 80 mg/m^2 , about 90 mg/m^2 , about 100 mg/m^2 to about 120 mg/m^2 .

c. Triazine

15 A triazine include but is not limited to such drugs as a dacabazine (DTIC; dimethyltriazenoimidaz olecarboxamide), used in the treatment of such cancers as a malignant melanoma, Hodgkin's disease and a soft-tissue sarcoma.

II. Antimetabolites

20 Antimetabolites disrupt DNA and RNA synthesis. Unlike alkylating agents, they specifically influence the cell cycle during S phase. They have used to combat chronic leukemias in addition to tumors of breast, ovary and the gastrointestinal tract. Antimetabolites can be differentiated into various categories, such as folic acid analogs, pyrimidine analogs and purine analogs and related inhibitory compounds. Antimetabolites include but are not limited to,
25 5-fluorouracil (5-FU), cytarabine (Ara-C), fludarabine, gemcitabine, and methotrexate.

i. Folic Acid Analogs

 Folic acid analogs include but are not limited to compounds such as methotrexate (amethopterin), which has been used in the treatment of cancers such as acute lymphocytic
30 leukemia, choriocarcinoma, mycosis fungoides, breast, head and neck, lung and osteogenic sarcoma.

ii. Pyrimidine Analogs

Pyrimidine analogs include such compounds as cytarabine (cytosine arabinoside), 5-fluorouracil (fluorouracil; 5-FU) and floxuridine (fluorode-oxyuridine; FudR). Cytarabine has been used in the treatment of cancers such as acute granulocytic leukemia and acute lymphocytic leukemias. Floxuridine and 5-fluorouracil have been used in the treatment of cancers such as breast, colon, stomach, pancreas, ovary, head and neck, urinary bladder and topical premalignant skin lesions.

5-Fluorouracil (5-FU) has the chemical name of 5-fluoro-2,4(1H,3H)-pyrimidinedione. Its mechanism of action is thought to be by blocking the methylation reaction of deoxyuridylic acid to thymidylic acid. Thus, 5-FU interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA). Since DNA and RNA are essential for cell division and proliferation, it is thought that the effect of 5-FU is to create a thymidine deficiency leading to cell death. Thus, the effect of 5-FU is found in cells that rapidly divide, a characteristic of metastatic cancers.

iii. Purine Analogs and Related Inhibitors

Purine analogs and related compounds include, but are not limited to, mercaptopurine (6-mercaptopurine; 6-MP), thioguanine (6-thioguanine; TG) and pentostatin (2-deoxycoformycin). Mercaptopurine has been used in acute lymphocytic, acute granulocytic and chronic granulocytic leukemias. Thioguanine has been used in the treatment of such cancers as acute granulocytic leukemia, acute lymphocytic leukemia and chronic lymphocytic leukemia. Pentostatin has been used in such cancers as hairy cell leukemias, mycosis fungoides and chronic lymphocytic leukemia.

III. Natural Products

Natural products generally refer to compounds originally isolated from a natural source, and identified as having a pharmacological activity. Such compounds, analogs and derivatives thereof may be, isolated from a natural source, chemically synthesized or recombinantly produced by any technique known to those of skill in the art. Natural products include such categories as mitotic inhibitors, antitumor antibiotics, enzymes and biological response modifiers.

i. Mitotic Inhibitors

Mitotic inhibitors include plant alkaloids and other natural agents that can inhibit either protein synthesis required for cell division or mitosis. They operate during a specific phase during the cell cycle. Mitotic inhibitors include, for example, docetaxel, etoposide (VP16),
5 teniposide, paclitaxel, taxol, vinblastine, vincristine, and vinorelbine.

a. Epipodophyllotoxins

Epipodophyllotoxins include such compounds as teniposide and VP16. VP16 is also known as etoposide and is used primarily for treatment of testicular tumors, in combination with
10 bleomycin and cisplatin, and in combination with cisplatin for small-cell carcinoma of the lung. Teniposide and VP16 are also active against cancers such as testis, other lung cancer, Hodgkin's disease, non-Hodgkin's lymphomas, acute granulocytic leukemia, acute nonlymphocytic leukemia, carcinoma of the breast, and Kaposi's sarcoma associated with acquired immunodeficiency syndrome (AIDS).

15 VP16 is available as a solution (*e.g.*, 20 mg/ml) for intravenous administration and as 50 mg, liquid-filled capsules for oral use. For small-cell carcinoma of the lung, the intravenous dose (in combination therapy) is can be as much as about 100 mg/m² or as little as about 2 mg/m², routinely about 35 mg/m², daily for about 4 days, to about 50 mg/m², daily for about 5 days have also been used. When given orally, the dose should be doubled. Hence the doses for small
20 cell lung carcinoma may be as high as about 200 mg/m² to about 250 mg/m². The intravenous dose for testicular cancer (in combination therapy) is about 50 mg/m² to about 100 mg/m² daily for about 5 days, or about 100 mg/m² on alternate days, for three doses. Cycles of therapy are usually repeated about every 3 to 4 weeks. The drug should be administered slowly (*e.g.*, about 30 minutes to about 60 minutes) as an infusion in order to avoid hypotension and bronchospasm,
25 which are probably due to the solvents used in the formulation.

b. Taxoids

Taxoids are a class of related compounds isolated from the bark of the ash tree, *Taxus brevifolia*. Taxoids include but are not limited to compounds such as docetaxel and paclitaxel.

30 Paclitaxel binds to tubulin (at a site distinct from that used by the vinca alkaloids) and promotes the assembly of microtubules. Paclitaxel is being evaluated clinically; it has activity against malignant melanoma and carcinoma of the ovary. In certain aspects, maximal doses are about 30 mg/m² per day for about 5 days or about 210 mg/m² to about 250 mg/m² given once about every 3 weeks.

c. Vinca Alkaloids

Vinca alkaloids are a type of plant alkaloid identified to have pharmaceutical activity. They include such compounds as vinblastine (VLB) and vincristine.

5

1. Vinblastine

Vinblastine is an example of a plant alkaloid that can be used for the treatment of cancer and precancer. When cells are incubated with vinblastine, dissolution of the microtubules occurs.

10 Unpredictable absorption has been reported after oral administration of vinblastine or vincristine. At the usual clinical doses the peak concentration of each drug in plasma is approximately 0.4 mM. Vinblastine and vincristine bind to plasma proteins. They are extensively concentrated in platelets and to a lesser extent in leukocytes and erythrocytes.

15 After intravenous injection, vinblastine has a multiphasic pattern of clearance from the plasma; after distribution, drug disappears from plasma with half-lives of approximately 1 and 20 hours. Vinblastine is metabolized in the liver to biologically active derivative desacetylvinblastine. Approximately 15% of an administered dose is detected intact in the urine, and about 10% is recovered in the feces after biliary excretion. Doses should be reduced in patients with hepatic dysfunction. At least a 50% reduction in dosage is indicated if the
20 concentration of bilirubin in plasma is greater than 3 mg/dl (about 50 mM).

Vinblastine sulfate is available in preparations for injection. When the drug is given intravenously; special precautions must be taken against subcutaneous extravasation, since this may cause painful irritation and ulceration. The drug should not be injected into an extremity with impaired circulation. After a single dose of 0.3 mg/kg of body weight, myelosuppression
25 reaches its maximum in about 7 days to about 10 days. If a moderate level of leukopenia (approximately 3000 cells/mm³) is not attained, the weekly dose may be increased gradually by increments of about 0.05 mg/kg of body weight. In regimens designed to cure testicular cancer, vinblastine is used in doses of about 0.3 mg/kg about every 3 weeks irrespective of blood cell counts or toxicity.

30 An important clinical use of vinblastine is with bleomycin and cisplatin in the curative therapy of metastatic testicular tumors. Beneficial responses have been reported in various lymphomas, particularly Hodgkin's disease, where significant improvement may be noted in 50 to 90% of cases. The effectiveness of vinblastine in a high proportion of lymphomas is not diminished when the disease is refractory to alkylating agents. It is also active in Kaposi's

sarcoma, testis cancer, neuroblastoma, and Letterer-Siwe disease (histiocytosis X), as well as in carcinoma of the breast and choriocarcinoma in women.

Doses of about 0.1 mg/kg to about 0.3 mg/kg can be administered or about 1.5 mg/m² to about 2 mg/m² can also be administered. Alternatively, about 0.1 mg/m², about 0.12 mg/m², about 0.14 mg/m², about 0.15 mg/m², about 0.2 mg/m², about 0.25 mg/m², about 0.5 mg/m², about 1.0 mg/m², about 1.2 mg/m², about 1.4 mg/m², about 1.5 mg/m², about 2.0 mg/m², about 2.5 mg/m², about 5.0 mg/m², about 6 mg/m², about 8 mg/m², about 9 mg/m², about 10 mg/m², to about 20 mg/m², can be given.

2. Vincristine

Vincristine blocks mitosis and produces metaphase arrest. It seems likely that most of the biological activities of this drug can be explained by its ability to bind specifically to tubulin and to block the ability of protein to polymerize into microtubules. Through disruption of the microtubules of the mitotic apparatus, cell division is arrested in metaphase. The inability to segregate chromosomes correctly during mitosis presumably leads to cell death.

The relatively low toxicity of vincristine for normal marrow cells and epithelial cells make this agent unusual among anti-neoplastic drugs, and it is often included in combination with other myelosuppressive agents. Unpredictable absorption has been reported after oral administration of vinblastine or vincristine. At the usual clinical doses the peak concentration of each drug in plasma is about 0.4 mM.

Vinblastine and vincristine bind to plasma proteins. They are extensively concentrated in platelets and to a lesser extent in leukocytes and erythrocytes. Vincristine has a multiphasic pattern of clearance from the plasma; the terminal half-life is about 24 hours. The drug is metabolized in the liver, but no biologically active derivatives have been identified. Doses should be reduced in patients with hepatic dysfunction. At least a 50% reduction in dosage is indicated if the concentration of bilirubin in plasma is greater than about 3 mg/dl (about 50 mM).

Vincristine sulfate is available as a solution (*e.g.*, 1 mg/ml) for intravenous injection. Vincristine used together with corticosteroids is presently the treatment of choice to induce remissions in childhood leukemia; the optimal dosages for these drugs appear to be vincristine, intravenously, about 2 mg/m² of body-surface area, weekly; and prednisone, orally, about 40 mg/m², daily. Adult patients with Hodgkin's disease or non-Hodgkin's lymphomas usually receive vincristine as a part of a complex protocol. When used in the MOPP regimen, the recommended dose of vincristine is about 1.4 mg/m². High doses of vincristine seem to be tolerated better by children with leukemia than by adults, who may experience sever

neurological toxicity. Administration of the drug more frequently than every 7 days or at higher doses seems to increase the toxic manifestations without proportional improvement in the response rate. Precautions should also be used to avoid extravasation during intravenous administration of vincristine. Vincristine (and vinblastine) can be infused into the arterial blood supply of tumors in doses several times larger than those that can be administered intravenously with comparable toxicity.

Vincristine has been effective in Hodgkin's disease and other lymphomas. Although it appears to be somewhat less beneficial than vinblastine when used alone in Hodgkin's disease, when used with mechlorethamine, prednisone, and procarbazine (the so-called MOPP regimen), it is the preferred treatment for the advanced stages (III and IV) of this disease. In non-Hodgkin's lymphomas, vincristine is an important agent, particularly when used with cyclophosphamide, bleomycin, doxorubicin, and prednisone. Vincristine is more useful than vinblastine in lymphocytic leukemia. Beneficial response have been reported in patients with a variety of other neoplasms, particularly Wilms' tumor, neuroblastoma, brain tumors, rhabdomyosarcoma, small cell lung, and carcinomas of the breast, bladder, and the male and female reproductive systems.

Doses of vincristine include about 0.01 mg/kg to about 0.03 mg/kg or about 0.4 mg/m² to about 1.4 mg/m² can be administered or about 1.5 mg/m² to about 2 mg/m² can also be administered. Alternatively, in certain embodiments, about 0.02 mg/m², about 0.05 mg/m², about 0.06 mg/m², about 0.07 mg/m², about 0.08 mg/m², about 0.1 mg/m², about 0.12 mg/m², about 0.14 mg/m², about 0.15 mg/m², about 0.2 mg/m², about 0.25 mg/m² can be given as a constant intravenous infusion.

d. Antitumor Antibiotics

Antitumor antibiotics have both antimicrobial and cytotoxic activity. These drugs also interfere with DNA by chemically inhibiting enzymes and mitosis or altering cellular membranes. These agents are not phase specific so they work in all phases of the cell cycle. Thus, they are widely used for a variety of cancers. Examples of antitumor antibiotics include, but are not limited to, bleomycin, dactinomycin, daunorubicin, doxorubicin (Adriamycin), plicamycin (mithramycin) and idarubicin. Widely used in clinical setting for the treatment of neoplasms these compounds generally are administered through intravenous bolus injections or orally.

1. Doxorubicin

Doxorubicin hydrochloride, 5,12-Naphthacenedione, (8*s-cis*)-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-hydrochloride (hydroxydaunorubicin hydrochloride, Adriamycin) is used in a wide antineoplastic spectrum. It binds to DNA and inhibits nucleic acid synthesis, inhibits mitosis and promotes chromosomal aberrations.

Administered alone, it is the drug of first choice for the treatment of thyroid adenoma and primary hepatocellular carcinoma. It is a component of 31 first-choice combinations for the treatment of diseases including ovarian, endometrial and breast tumors, bronchogenic oat-cell carcinoma, non-small cell lung carcinoma, stomach, genitourinary, thyroid, gastric adenocarcinoma, retinoblastoma, neuroblastoma, mycosis fungoides, pancreatic carcinoma, prostatic carcinoma, bladder carcinoma, myeloma, diffuse histiocytic lymphoma, Wilms' tumor, Hodgkin's disease, adrenal tumors, osteogenic sarcoma, soft tissue sarcoma, Ewing's sarcoma, rhabdomyosarcoma and acute lymphocytic leukemia. It is an alternative drug for the treatment of other diseases such as islet cell, cervical, testicular and adrenocortical cancers. It is also an immunosuppressant.

Doxorubicin is absorbed poorly and is preferably administered intravenously. The pharmacokinetics are multicompartamental. Distribution phases have half-lives of 12 minutes and 3.3 hours. The elimination half-life is about 30 hours, with about 40% to about 50% secreted into the bile. Most of the remainder is metabolized in the liver, partly to an active metabolite (doxorubicinol), but a few percent is excreted into the urine. In the presence of liver impairment, the dose should be reduced.

In certain embodiments, appropriate intravenous doses are, adult, about 60 mg/m² to about 75 mg/m² at about 21-day intervals or about 25 mg/m² to about 30 mg/m² on each of 2 or 3 successive days repeated at about 3 week to about 4 week intervals or about 20 mg/m² once a week. The lowest dose should be used in elderly patients, when there is prior bone-marrow depression caused by prior chemotherapy or neoplastic marrow invasion, or when the drug is combined with other myelopoietic suppressant drugs. The dose should be reduced by about 50% if the serum bilirubin lies between about 1.2 mg/dL and about 3 mg/dL and by about 75% if above about 3 mg/dL. The lifetime total dose should not exceed about 550 mg/m² in patients with normal heart function and about 400 mg/m² in persons having received mediastinal irradiation. In certain embodiments, an alternative dose regiment may comprise about 30 mg/m² on each of 3 consecutive days, repeated about every 4 week. Exemplary doses may be about 10 mg/m², about 20 mg/m², about 30 mg/m², about 50 mg/m², about 100 mg/m², about

150 mg/m², about 175 mg/m², about 200 mg/m², about 225 mg/m², about 250 mg/m², about 275 mg/m², about 300 mg/m², about 350 mg/m², about 400 mg/m², about 425 mg/m², about 450 mg/m², about 475 mg/m², to about 500 mg/m².

2. Daunorubicin

Daunorubicin hydrochloride, 5,12-Naphthacenedione, (8*S-cis*)-8-acetyl-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexanopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-10-methoxy-, hydrochloride; also termed cerubidine and available from Wyeth. Daunorubicin (daunomycin; rubidomycin) intercalates into DNA, blocks DAN-directed RNA polymerase and inhibits DNA synthesis. It can prevent cell division in doses that do not interfere with nucleic acid synthesis.

In combination with other drugs it is often included in the first-choice chemotherapy of diseases such as, for example, acute granulocytic leukemia, acute myelocytic leukemia in adults (for induction of remission), acute lymphocytic leukemia and the acute phase of chronic myelocytic leukemia. Oral absorption is poor, and it preferably given by other methods (*e.g.*, intravenously). The half-life of distribution is 45 minutes and of elimination, about 19 hours. The half-life of its active metabolite, daunorubicinol, is about 27 hours. Daunorubicin is metabolized mostly in the liver and also secreted into the bile (about 40%). Dosage must be reduced in liver or renal insufficiencies.

Generally, suitable intravenous doses are (base equivalent): adult, younger than 60 years, about 45 mg/m²/day (about 30 mg/m² for patients older than 60 year.) for about 1 day, about 2 days or about 3 days about every 3 weeks or 4 weeks or about 0.8 mg/kg/day for about 3 days, about 4 days, about 5 days to about 6 days about every 3 weeks or about 4 weeks; no more than about 550 mg/m² should be given in a lifetime, except only about 450 mg/m² if there has been chest irradiation; children, about 25 mg/m² once a week unless the age is less than 2 years. or the body surface less than about 0.5 m, in which case the weight-based adult schedule is used. It is available in injectable dosage forms (base equivalent) of about 20 mg (as the base equivalent to about 21.4 mg of the hydrochloride). Exemplary doses may be about 10 mg/m², about 20 mg/m², about 30 mg/m², about 50 mg/m², about 100 mg/m², about 150 mg/m², about 175 mg/m², about 200 mg/m², about 225 mg/m², about 250 mg/m², about 275 mg/m², about 300 mg/m², about 350 mg/m², about 400 mg/m², about 425 mg/m², about 450 mg/m², about 475 mg/m², to about 500 mg/m².

3. Mitomycin

Mitomycin (also known as mutamycin and/or mitomycin-C) is an antibiotic isolated from the broth of *Streptomyces caespitosus* which has been shown to have antitumor activity. The compound is heat stable, has a high melting point, and is freely soluble in organic solvents.

5 Mitomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Mitomycin has been used in tumors such as stomach, cervix, colon, breast, pancreas, bladder and head and neck.

10 In humans, mitomycin is rapidly cleared from the serum after intravenous administration. Time required to reduce the serum concentration by about 50% after a 30 mg. bolus injection is 17 minutes. After injection of 30 mg, 20 mg, or 10 mg I.V., the maximal serum concentrations were 2.4 mg/mL, 1.7 mg/mL, and 0.52 mg/mL, respectively. Clearance is effected primarily by metabolism in the liver, but metabolism occurs in other tissues as well. The rate of clearance is
15 inversely proportional to the maximal serum concentration because, it is thought, of saturation of the degradative pathways. Approximately 10% of a dose of mitomycin is excreted unchanged in the urine. Since metabolic pathways are saturated at relatively low doses, the percent of a dose excreted in urine increases with increasing dose. In children, excretion of intravenously administered mitomycin is similar.

4. Actinomycin D

Actinomycin D (Dactinomycin) [50-76-0]; $C_{62}H_{86}N_{12}O_{16}$ (1255.43) is an antineoplastic drug that inhibits DNA-dependent RNA polymerase. It is often a component of first-choice combinations for treatment of diseases such as, for example, choriocarcinoma, embryonal
25 rhabdomyosarcoma, testicular tumor, Kaposi's sarcoma and Wilms' tumor. Tumors that fail to respond to systemic treatment sometimes respond to local perfusion. Dactinomycin potentiates radiotherapy. It is a secondary (efferent) immunosuppressive.

In certain specific aspects, actinomycin D is used in combination with agents such as, for example, primary surgery, radiotherapy, and other drugs, particularly vincristine and
30 cyclophosphamide. Antineoplastic activity has also been noted in Ewing's tumor, Kaposi's sarcoma, and soft-tissue sarcomas. Dactinomycin can be effective in women with advanced cases of choriocarcinoma. It also produces consistent responses in combination with chlorambucil and methotrexate in patients with metastatic testicular carcinomas. A response may sometimes be observed in patients with Hodgkin's disease and non-Hodgkin's lymphomas.

Dactinomycin has also been used to inhibit immunological responses, particularly the rejection of renal transplants.

Half of the dose is excreted intact into the bile and 10% into the urine; the half-life is about 36 hours. The drug does not pass the blood-brain barrier. Actinomycin D is supplied as a lyophilized powder (0.5 mg in each vial). The usual daily dose is about 10 mg/kg to about 15 mg/kg; this is given intravenously for about 5 days; if no manifestations of toxicity are encountered, additional courses may be given at intervals of about 3 weeks to about 4 weeks. Daily injections of about 100 mg to about 400 mg have been given to children for about 10 days to about 14 days; in other regimens, about 3 mg/kg to about 6 mg/kg, for a total of about 125 mg/kg, and weekly maintenance doses of about 7.5 mg/kg have been used. Although it is safer to administer the drug into the tubing of an intravenous infusion, direct intravenous injections have been given, with the precaution of discarding the needle used to withdraw the drug from the vial in order to avoid subcutaneous reaction. Exemplary doses may be about 100 mg/m², about 150 mg/m², about 175 mg/m², about 200 mg/m², about 225 mg/m², about 250 mg/m², about 275 mg/m², about 300 mg/m², about 350 mg/m², about 400 mg/m², about 425 mg/m², about 450 mg/m², about 475 mg/m², to about 500 mg/m².

5. Bleomycin

Bleomycin is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of *Streptomyces verticillus*. Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis.

In mice, high concentrations of bleomycin are found in the skin, lungs, kidneys, peritoneum, and lymphatics. Tumor cells of the skin and lungs have been found to have high concentrations of bleomycin in contrast to the low concentrations found in hematopoietic tissue. The low concentrations of bleomycin found in bone marrow may be related to high levels of bleomycin degradative enzymes found in that tissue.

In patients with a creatinine clearance of greater than about 35 mL per minute, the serum or plasma terminal elimination half-life of bleomycin is approximately 115 minutes. In patients with a creatinine clearance of less than about 35 mL per minute, the plasma or serum terminal elimination half-life increases exponentially as the creatinine clearance decreases. In humans, about 60% to about 70% of an administered dose is recovered in the urine as active bleomycin. In specific embodiments, bleomycin may be given by the intramuscular, intravenous, or subcutaneous routes. It is freely soluble in water. Because of the possibility of an anaphylactoid

reaction, lymphoma patients should be treated with two units or less for the first two doses. If no acute reaction occurs, then the regular dosage schedule may be followed.

In preferred aspects, bleomycin should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents in squamous cell carcinoma such as head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingiva, epiglottis, larynx), esophagus, lung and genitourinary tract, Hodgkin's disease, non-Hodgkin's lymphoma, skin, penis, cervix, and vulva. It has also been used in the treatment of lymphomas and testicular carcinoma.

Improvement of Hodgkin's Disease and testicular tumors is prompt and noted within 2 weeks. If no improvement is seen by this time, improvement is unlikely. Squamous cell cancers respond more slowly, sometimes requiring as long as 3 weeks before any improvement is noted.

IV. Miscellaneous Agents

Some chemotherapy agents do not qualify into the previous categories based on their activities. They include, but are not limited to, platinum coordination complexes, anthracenedione, substituted urea, methyl hydrazine derivative, adrenalcortical suppressant, amsacrine, L-asparaginase, and tretinoin. It is contemplated that they are included within the compositions and methods of the present invention for use in combination therapies.

i. Platinum Coordination Complexes

Platinum coordination complexes include such compounds as carboplatin and cisplatin (*cis*-DDP). Cisplatin has been widely used to treat cancers such as, for example, metastatic testicular or ovarian carcinoma, advanced bladder cancer, head or neck cancer, cervical cancer, lung cancer or other tumors. Cisplatin is not absorbed orally and must therefore be delivered *via* other routes, such as for example, intravenous, subcutaneous, intratumoral or intraperitoneal injection. Cisplatin can be used alone or in combination with other agents, with efficacious doses used in clinical applications of about 15 mg/m² to about 20 mg/m² for 5 days every three weeks for a total of three courses being contemplated in certain embodiments. Doses may be, for example, about 0.50 mg/m², about 1.0 mg/m², about 1.50 mg/m², about 1.75 mg/m², about 2.0 mg/m², about 3.0 mg/m², about 4.0 mg/m², about 5.0 mg/m², to about 10 mg/m².

The present inventors have found that cisplatin, which stimulates ROI production, induces the CArG elements of the Egr-1 promoter. For example, cisplatin induced the production of TNF- α in human and rodent cancer cells infected with an adenoviral vector

29748-2

encoding the CArG elements of the Egr-1 promoter ligated upstream to a cDNA encoding TNF- α . Thus, the present invention provides a new approach that combines the use of chemotherapeutic agents that can produce ROI or DNA damage, such as cisplatin, with the temporal and spatial control of gene therapy using antitumor genes.

5

ii. Other Agents

Anthracenediones, such as mitoxantrone, have been used for treating acute granulocytic leukemia and breast cancer. A substituted urea such as hydroxyurea has been used in treating chronic granulocytic leukemia, polycythemia vera, essential thrombocytosis and malignant melanoma. A methyl hydrazine derivative such as procarbazine (N-methylhydrazine, MIH) has been used in the treatment of Hodgkin's disease. An adrenocortical suppressant such as mitotane has been used to treat adrenal cortex cancer, while aminoglutethimide has been used to treat Hodgkin's disease.

15

V. Doses

Doses for DNA damaging agents are well known to those of skill in the art (see for example, the "Physicians Desk Reference", Goodman & Gilman's "The Pharmacological Basis of Therapeutics", "Remington's Pharmaceutical Sciences", and "The Merck Index, Eleventh Edition"), and may be combined with the invention in light of the disclosures herein. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Examples of specific chemotherapeutic agents and dose regimes are also described herein. Of course, all of these dosages and agents described herein are exemplary rather than limiting, and other doses or agents may be used by a skilled artisan for a specific patient or application. Any dosage in-between these points, or range derivable therein is also expected to be of use in the invention.

30

C. Therapeutic Genes

I. Tumor Suppressors

p53 currently is recognized as a tumor suppressor gene. High levels of mutant p53 have been found in many cells transformed by chemical carcinogenesis, ultraviolet radiation, and several viruses. The p53 gene is a frequent target of mutational inactivation in a wide variety of human tumors and is already documented to be the most frequently-mutated gene in common

human cancers. It is mutated in over 50% of human NSCLC (Hollstein *et al.*, 1991) and in a wide spectrum of other tumors.

The p53 gene encodes a 393-amino acid phosphoprotein that can form complexes with host proteins such as SV40 large-T antigen and adenoviral E1B. The protein is found in normal tissues and cells, but at concentrations which are minute by comparison with transformed cells or tumor tissue. Interestingly, wild-type p53 appears to be important in regulating cell growth and division. Overexpression of wild-type p53 has been shown in some cases to be anti-proliferative in human tumor cell lines. Thus, p53 can act as a negative regulator of cell growth (Weinberg, 1991) and may directly suppress uncontrolled cell growth or indirectly activate genes that suppress this growth. Thus, absence or inactivation of wild-type p53 may contribute to transformation. However, some studies indicate that the presence of mutant p53 may be necessary for full expression of the transforming potential of the gene.

Wild-type p53 is recognized as an important growth regulator in many cell types. Missense mutations are common for the p53 gene and are essential for the transforming ability of the oncogene. A single genetic change prompted by point mutations can create carcinogenic p53, in as much as mutations in p53 are known to abrogate the tumor suppressor capability of wild-type p53. Unlike other oncogenes, however, p53 point mutations are known to occur in at least 30 distinct codons, often creating dominant alleles that produce shifts in cell phenotype without a reduction to homozygosity. Additionally, many of these dominant negative alleles appear to be tolerated in the organism and passed on in the germ line. Various mutant alleles appear to range from minimally dysfunctional to strongly penetrant, dominant negative alleles (Weinberg, 1991).

Casey and colleagues have reported that transfection of DNA encoding wild-type p53 into two human breast cancer cell lines restores growth suppression control in such cells (Casey *et al.*, 1991). A similar effect also has been demonstrated on transfection of wild-type, but not mutant, p53 into human lung cancer cell lines (Takahasi *et al.*, 1992). p53 appears dominant over the mutant gene and will select against proliferation when transfected into cells with the mutant gene. Normal expression of the transfected p53 does not affect the growth of normal or non-malignant cells with endogenous p53. Thus, such constructs might be taken up by normal cells without adverse effects. It is thus proposed that the treatment of p53-associated cancers with wild-type p53 will reduce the number of malignant cells or their growth rate.

The major transitions of the eukaryotic cell cycle are triggered by cyclin-dependent kinases, or CDK's. One CDK, cyclin-dependent kinase 4 (CDK4), regulates progression through the G₁. The activity of this enzyme may be to phosphorylate Rb at late G₁. The activity

of CDK4 is controlled by an activating subunit, D-type cyclin, and by an inhibitory subunit p16^{INK4}. The p16^{INK4} has been biochemically characterized as a protein that specifically binds to and inhibits CDK4, and thus may regulate Rb phosphorylation (Serrano *et al.*, 1993; Serrano *et al.*, 1995). Since the p16^{INK4} protein is a CDK4 inhibitor (Serrano, 1993), deletion of this gene
5 may increase the activity of CDK4, resulting in hyperphosphorylation of the Rb protein. p16 also is known to regulate the function of CDK6.

p16^{INK4} belongs to a newly described class of CDK-inhibitory proteins that also includes p15^{INK4B}, p21^{WAF1}, and p27^{KIP1}. The p16^{INK4} gene maps to 9p21, a chromosome region frequently deleted in many tumor types. Homozygous deletions and mutations of the p16^{INK4}
10 gene are frequent in human tumor cell lines. This evidence suggests that the p16^{INK4} gene is a tumor suppressor gene. This interpretation has been challenged, however, by the observation that the frequency of the p16^{INK4} gene alterations is much lower in primary uncultured tumors than in cultured cell lines (Caldas *et al.*, 1994; Cheng *et al.*, 1994; Hussussian *et al.*, 1994; Kamb *et al.*, 1994; Kamb *et al.*, 1994; Mori *et al.*, 1994; Okamoto *et al.*, 1994; Nobori *et al.*, 1995;
15 Orlow *et al.*, 1994; Arap *et al.*, 1995). However, it was later shown that while the p16 gene was intact in many primary tumors, there were other mechanisms that prevented p16 protein expression in a large percentage of some tumor types. p16 promoter hypermethylation is one of these mechanisms (Merlo *et al.*, 1995; Herman, 1995; Gonzalez-Zulueta, 1995). Restoration of wild-type p16^{INK4} function by transfection with a plasmid expression vector reduced colony
20 formation by some human cancer cell lines (Okamoto, 1994; Arap, 1995). Delivery of p16 with adenovirus vectors inhibits proliferation of some human cancer lines and reduces the growth of human tumor xenografts.

C-CAM is expressed in virtually all epithelial cells (Odin and Obrink, 1987). C-CAM, with an apparent molecular weight of 105 kD, was originally isolated from the plasma membrane
25 of the rat hepatocyte by its reaction with specific antibodies that neutralize cell aggregation (Obrink, 1991). Recent studies indicate that, structurally, C-CAM belongs to the immunoglobulin (Ig) superfamily and its sequence is highly homologous to carcinoembryonic antigen (CEA) (Lin and Guidotti, 1989). Using a baculovirus expression system, Cheung *et al.* (1993) demonstrated that the first Ig domain of C-CAM is critical for cell adhesive activity.

30 Cell adhesion molecules, or CAM's are known to be involved in a complex network of molecular interactions that regulate organ development and cell differentiation (Edelman, 1985). Recent data indicate that aberrant expression of CAM's maybe involved in the tumorigenesis of several neoplasms; for example, decreased expression of E-cadherin, which is predominantly expressed in epithelial cells, is associated with the progression of several kinds of neoplasms

(Edelman and Crossin, 1991; Frixen *et al.*, 1991; Bussemakers *et al.*, 1992; Matsura *et al.*, 1992; Umbas *et al.*, 1992). Also, Giancotti and Ruoslahti (1990) demonstrated that increasing expression of $\alpha_5\beta_1$ integrin by gene transfer can reduce tumorigenicity of Chinese hamster ovary cells *in vivo*. C-CAM now has been shown to suppress tumor growth *in vitro* and *in vivo*.

5 Other tumor suppressors that may be employed according to the present invention include p21, p15, BRCA1, BRCA2, IRF-1, PTEN, RB, APC, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, zac1, p73, VHL, FCC, MCC, DBCCR1, DCP4 and p57.

II. Inducers of Apoptosis

10 Inducers of apoptosis, such as Bax, Bak, Bcl-X_s, Bad, Bim, Bik, Bid, Harakiri, Ad E1B, Bad, ICE-CED3 proteases, TRAIL, SARP-2 and apoptin, similarly could find use according to the present invention. In addition, the delivery and regulated expression of cytotoxic genes have been described in the U.S. Patent Application entitled, "Induction of Apoptotic or Cytotoxic Gene Expression by Adenoviral Mediated Gene Codelivery," filed March 11, 1999 (specifically
15 incorporated herein by reference).

III. Enzymes

Various enzyme genes are of interest according to the present invention. Such enzymes include cytosine deaminase, adenosine deaminase, hypoxanthine-guanine
20 phosphoribosyltransferase, and human thymidine kinase.

IV. Cytokines, Hormones and Growth Factors

Another class of genes that is contemplated to be inserted into the vectors of the present invention include interleukins and cytokines. Interleukin 1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7,
25 IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, β -interferon, α -interferon, γ -interferon, angiostatin, thrombospondin, endostatin, METH-1, METH-2, GM-CSF, G-CSF, M-CSF and tumor necrosis factor (TNF).

TNF- α is a cytokine secreted by macrophages and other hematopoietic cells that has antitumor activity in animal studies (Old, 1985; Fiers, 1991). TNF- α is cytotoxic for many
30 malignant cells and also plays an important role in the defense against viral, bacterial and parasitic infections and in autoimmune responses (Fiers, 1991). A direct toxic effect on tumor cells, as well as cytotoxic and thrombotic effects on the tumor vasculature, mediate the antitumor effects of TNF- α (Watanabe *et al.*, 1988; Tartaglia *et al.*, 1993; Robaye *et al.*, 1991; Havell *et al.*, 1988; Obrador *et al.*, 2001; Slungaard *et al.*, 1990; Mauceri *et al.*, 2002). The combination

of TNF- α with chemotherapeutic agents, such as cisplatin and adriamycin, that damage DNA has demonstrated synergistic effects in experimental models (Duan *et al.*, 2001; Bonavida *et al.*, 1990). Recently, isolated limb perfusion with melphalan, a bi-functional alkylating agent, and TNF- α has been reported to be a successful therapeutic strategy for limb sarcomas and melanomas (Thom *et al.*, 1995). However, systemic toxicities have limited the use of TNF- α in human cancer therapy (Spriggs *et al.*, 1988).

The present invention provides the chemo-induction of TNF- α under the control of the inducible Egr-1 promoter, which can be induced by ROI's, damaged DNA and IR, by a chemotherapeutic agent. Studies in mice models of cancer and human cancer cells show that the chemo-induction of TNF- α in itself did not cause any toxicity.

V. Toxins

Various toxins are also contemplated to be useful as part of the expression vectors of the present invention, these toxins include bacterial toxins such as ricin A-chain (Burbage, 1997), diphtheria toxin A (Massuda *et al.*, 1997; Lidor, 1997), pertussis toxin A subunit, *E. coli* enterotoxin toxin A subunit, cholera toxin A subunit and pseudomonas toxin c-terminal. Recently, it was demonstrated that transfection of a plasmid containing the fusion protein regulatable diphtheria toxin A chain gene was cytotoxic for cancer cells. Thus, gene transfer of regulated toxin genes might also be applied to the treatment of cancers (Massuda *et al.*, 1997).

VI. Antisense Constructs

Antisense methodology takes advantage of the fact that nucleic acids tend to pair with "complementary" sequences. By complementary, it is meant that polynucleotides are those which are capable of base-pairing according to the standard Watson-Crick complementarity rules. That is, the larger purines will base pair with the smaller pyrimidines to form combinations of guanine paired with cytosine (G:C) and adenine paired with either thymine (A:T) in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA. Inclusion of less common bases such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine and others in hybridizing sequences does not interfere with pairing.

Targeting double-stranded (ds) DNA with polynucleotides leads to triple-helix formation; targeting RNA will lead to double-helix formation. Antisense polynucleotides, when introduced into a target cell, specifically bind to their target polynucleotide and interfere with transcription, RNA processing, transport, translation and/or stability. Antisense RNA constructs, or DNA encoding such antisense RNA's, may be employed to inhibit gene transcription or translation or

both within a host cell, either *in vitro* or *in vivo*, such as within a host animal, including a human subject.

Antisense constructs may be designed to bind to the promoter and other control regions, exons, introns or even exon-intron boundaries of a gene. It is contemplated that the most effective antisense constructs will include regions complementary to intron/exon splice junctions. Thus, it is proposed that a preferred embodiment includes an antisense construct with complementarity to regions within 50-200 bases of an intron-exon splice junction. It has been observed that some exon sequences can be included in the construct without seriously affecting the target selectivity thereof. The amount of exonic material included will vary depending on the particular exon and intron sequences used. One can readily test whether too much exon DNA is included simply by testing the constructs *in vitro* to determine whether normal cellular function is affected or whether the expression of related genes having complementary sequences is affected.

As stated above, "complementary" or "antisense" means polynucleotide sequences that are substantially complementary over their entire length and have very few base mismatches. For example, sequences of fifteen bases in length may be termed complementary when they have complementary nucleotides at thirteen or fourteen positions. Naturally, sequences which are completely complementary will be sequences which are entirely complementary throughout their entire length and have no base mismatches. Other sequences with lower degrees of homology also are contemplated. For example, an antisense construct which has limited regions of high homology, but also contains a non-homologous region (*e.g.*, ribozyme; see below) could be designed. These molecules, though having less than 50% homology, would bind to target sequences under appropriate conditions.

It may be advantageous to combine portions of genomic DNA with cDNA or synthetic sequences to generate specific constructs. For example, where an intron is desired in the ultimate construct, a genomic clone will need to be used. The cDNA or a synthesized polynucleotide may provide more convenient restriction sites for the remaining portion of the construct and, therefore, would be used for the rest of the sequence.

Particular oncogenes that are targets for antisense constructs are *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *hst*, *gsp*, *bcl-2* and *abl*. Also contemplated to be useful will be anti-apoptotic genes and angiogenesis promoters.

29748-2

VII. Ribozymes

Although proteins traditionally have been used for catalysis of nucleic acids, another class of macromolecules has emerged as useful in this endeavor. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cook, 1987; Gerlach *et al.*, 1987; Forster and Symons, 1987). For example, a large number of ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Michel and Westhof, 1990; Reinhold-Hurek and Shub, 1992). This specificity has been attributed to the requirement that the substrate bind *via* specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme prior to chemical reaction.

Ribozyme catalysis has primarily been observed as part of sequence-specific cleavage/ligation reactions involving nucleic acids (Joyce, 1989; Cook *et al.*, 1981). For example, U.S. Patent 5,354,855 reports that certain ribozymes can act as endonucleases with a sequence specificity greater than that of known ribonucleases and approaching that of the DNA restriction enzymes. Thus, sequence-specific ribozyme-mediated inhibition of gene expression may be particularly suited to therapeutic applications (Scanlon *et al.*, 1991; Sarver *et al.*, 1990). Recently, it was reported that ribozymes elicited genetic changes in some cells lines to which they were applied; the altered genes included the oncogenes H-ras, c-fos and genes of HIV. Most of this work involved the modification of a target mRNA, based on a specific mutant codon that is cleaved by a specific ribozyme. Targets for this embodiment will include angiogenic genes such as VEGFs and angiopoietins as well as the oncogenes (*e.g.*, *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *hst*, *gsp*, *bcl-2*, *EGFR*, *grb2* and *abl*).

VIII. Single Chain Antibodies

In yet another embodiment, one gene may comprise a single-chain antibody. Methods for the production of single-chain antibodies are well known to those of skill in the art. The skilled artisan is referred to U.S. Patent 5,359,046, for such methods. A single chain antibody is created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule.

Single-chain antibody variable fragments (scFvs) in which the C-terminus of one variable domain is tethered to the N-terminus of the other *via* a 15 to 25 amino acid peptide or linker, have been developed without significantly disrupting antigen binding or specificity of the

binding (Bedzyk *et al.*, 1990; Chaudhary *et al.*, 1990). These Fvs lack the constant regions (Fc) present in the heavy and light chains of the native antibody.

Antibodies to a wide variety of molecules are contemplated, such as oncogenes, growth factors, hormones, enzymes, transcription factors or receptors. Also contemplated are secreted antibodies, targeted to serum, against angiogenic factors (VEGF/VSP; β FGF; α FGF) and endothelial antigens necessary for angiogenesis (*i.e.*, V3 integrin). Specifically contemplated are growth factors such as transforming growth factor and platelet derived growth factor.

IX. Cell Cycle Regulators

Cell cycle regulators provide possible advantages, when combined with other genes. Such cell cycle regulators include p27, p21, p57, p18, p73, p19, p15, E2F-1, E2F-2, E2F-3, p107, p130 and E2F-4. Other cell cycle regulators include anti-angiogenic proteins, such as soluble Flt1 (dominant negative soluble VEGF receptor), soluble Wnt receptors, soluble Tie2/Tek receptor, soluble hemopexin domain of matrix metalloprotease 2 and soluble receptors of other angiogenic cytokines (*e.g.* VEGFR1/KDR, VEGFR3/Flt4, both VEGF receptors).

X. Chemokines

Genes that code for chemokines also may be used in the present invention. Chemokines generally act as chemoattractants to recruit immune effector cells to the site of chemokine expression. It may be advantageous to express a particular chemokine gene in combination with, for example, a cytokine gene, to enhance the recruitment of other immune system components to the site of treatment. Such chemokines include RANTES, MCAF, MIP1- α , MIP1- β and IP-10. The skilled artisan will recognize that certain cytokines are also known to have chemoattractant effects and could also be classified under the term chemokines.

D. Expression Constructs

I. Vectors

The term "vector" is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. A nucleic acid sequence can be "exogenous," which means that it is foreign to the cell into which the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (*e.g.*, YACs). One of skill in the art would be well equipped to construct

29748-2

a vector through standard recombinant techniques (see, for example, Goodbourn and Maniatis *et al.*, 1988 and Ausubel *et al.*, 1994).

The term "expression vector" refers to any type of genetic construct comprising a nucleic acid coding for a RNA capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules or ribozymes. Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host cell. According to the present invention, the vectors will contain sufficient portions of the Egr-1 promoter to confer chemical inducibility. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described *infra*.

i. Initiation Signals and Internal Ribosome Binding Sites

A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame" with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements.

In certain embodiments of the invention, the use of internal ribosome entry sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements from two members of the picornavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and Sarnow, 1991). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to

29748-2

transcribe a single message (see U.S. Patent Nos. 5,925,565 and 5,935,819).

ii. Multiple Cloning Sites

5 Vectors can include a multiple cloning site (MCS), which is a nucleic acid region that contains multiple restriction enzyme sites, any of which can be used in conjunction with standard recombinant technology to digest the vector (see, for example, Carbonelli *et al.*, 1999, Levenson *et al.*, 1998, and Cocea, 1997). "Restriction enzyme digestion" refers to catalytic cleavage of a nucleic acid molecule with an enzyme that functions only at
10 specific locations in a nucleic acid molecule. Many of these restriction enzymes are commercially available. Use of such enzymes is widely understood by those of skill in the art. Frequently, a vector is linearized or fragmented using a restriction enzyme that cuts within the MCS to enable exogenous sequences to be ligated to the vector. "Ligation" refers to the process of forming phosphodiester bonds between two nucleic acid fragments, which may or may not be
15 contiguous with each other. Techniques involving restriction enzymes and ligation reactions are well known to those of skill in the art of recombinant technology.

iii. Splicing Sites

Most transcribed eukaryotic RNA molecules will undergo RNA splicing to remove
20 introns from the primary transcripts. Vectors containing genomic eukaryotic sequences may require donor and/or acceptor splicing sites to ensure proper processing of the transcript for protein expression (see, for example, Chandler *et al.*, 1997).

iv. Termination Signals

25 The vectors or constructs of the present invention will generally comprise at least one termination signal. A "termination signal" or "terminator" is comprised of the DNA sequences involved in specific termination of an RNA transcript by an RNA polymerase. Thus, in certain embodiments a termination signal that ends the production of an RNA transcript is contemplated. A terminator may be necessary *in vivo* to achieve desirable message levels.

30 In eukaryotic systems, the terminator region may also comprise specific DNA sequences that permit site-specific cleavage of the new transcript so as to expose a polyadenylation site. This signals a specialized endogenous polymerase to add a stretch of about 200 A residues (polyA) to the 3' end of the transcript. RNA molecules modified with this polyA tail appear to more stable and are translated more efficiently. Thus, in other embodiments involving

eukaryotes, it is preferred that that terminator comprises a signal for the cleavage of the RNA, and it is more preferred that the terminator signal promotes polyadenylation of the message. The terminator and/or polyadenylation site elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

5 Terminators contemplated for use in the invention include any known terminator of transcription described herein or known to one of ordinary skill in the art, including but not limited to, for example, the termination sequences of genes, such as for example the bovine growth hormone terminator or viral termination sequences, such as for example the SV40 terminator. In certain embodiments, the termination signal may be a lack of transcribable or
10 translatable sequence, such as due to a sequence truncation.

v. Polyadenylation Signals

In expression, particularly eukaryotic expression, one will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the
15 polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed. Preferred embodiments include the SV40 polyadenylation signal or the bovine growth hormone polyadenylation signal, convenient and known to function well in various target cells. Polyadenylation may increase the stability of the transcript or may facilitate cytoplasmic transport.

20

vi. Origins of Replication

In order to propagate a vector in a host cell, it may contain one or more origins of replication sites (often termed "ori"), which is a specific nucleic acid sequence at which replication is initiated. Alternatively an autonomously replicating sequence (ARS) can be
25 employed if the host cell is yeast.

vii. Selectable and Screenable Markers

In certain embodiments of the invention, cells containing a nucleic acid construct of the present invention may be identified *in vitro* or *in vivo* by including a marker in the expression
30 vector. Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression vector. Generally, a selectable marker is one that confers a property that allows for selection. A positive selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in

which its presence prevents its selection. An example of a positive selectable marker is a drug resistance marker.

Usually the inclusion of a drug selection marker aids in the cloning and identification of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers including screenable markers such as GFP, whose basis is colorimetric analysis, are also contemplated. Alternatively, screenable enzymes such as herpes simplex virus thymidine kinase (*tk*) or chloramphenicol acetyltransferase (CAT) may be utilized. One of skill in the art would also know how to employ immunologic markers, possibly in conjunction with FACS analysis. The marker used is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a gene product. Further examples of selectable and screenable markers are well known to one of skill in the art.

viii. Plasmid Vectors

In certain embodiments, a plasmid vector is contemplated for use to transform a host cell. In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. In a non-limiting example, *E. coli* is often transformed using derivatives of pBR322, a plasmid derived from an *E. coli* species. pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, for example, promoters which can be used by the microbial organism for expression of its own proteins.

In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, the phage lambda GEMTM-11 may be utilized in making a recombinant phage vector which can be used to transform host cells, such as, for example, *E. coli* LE392.

Further useful plasmid vectors include pIN vectors (Inouye *et al.*, 1985); and pGEX vectors, for use in generating glutathione S-transferase (GST) soluble fusion proteins for later purification and separation or cleavage. Other suitable fusion proteins are those with β -galactosidase, ubiquitin, and the like.

Bacterial host cells, for example, *E. coli*, comprising the expression vector, are grown in any of a number of suitable media, for example, LB. The expression of the recombinant protein in certain vectors may be induced, as would be understood by those of skill in the art, by contacting a host cell with an agent specific for certain promoters, *e.g.*, by adding IPTG to the media or by switching incubation to a higher temperature. After culturing the bacteria for a further period, generally of between 2 and 24 h, the cells are collected by centrifugation and washed to remove residual media.

ix. Viral Vectors

The ability of certain viruses to infect cells or enter cells *via* receptor-mediated endocytosis, and to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign nucleic acids into cells (*e.g.*, mammalian cells). Non-limiting examples of virus vectors that may be used to deliver a nucleic acid of the present invention are described below.

a. Adenoviral Vectors

A particular method for delivery of the nucleic acid involves the use of an adenovirus expression vector. Although adenovirus vectors are known to have a low capacity for integration into genomic DNA, this feature is counterbalanced by the high efficiency of gene transfer afforded by these vectors. "Adenovirus expression vector" is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to ultimately express a tissue or cell-specific construct that has been cloned therein. Knowledge of the genetic organization of adenovirus, a 36 kb, linear, double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kb (Grunhaus and Horwitz, 1992).

b. AAV Vectors

The nucleic acid may be introduced into the cell using adenovirus assisted transfection. Increased transfection efficiencies have been reported in cell systems using adenovirus coupled systems (Kelleher and Vos, 1994; Cotten *et al.*, 1992; Curiel, 1994). Adeno-associated virus (AAV) is an attractive vector system for use according to the present invention as it has a high frequency of integration and it can infect nondividing cells, thus making it useful for delivery of genes into mammalian cells, for example, in tissue culture (Muzyczka, 1992) or *in vivo*. AAV has a broad host range for infectivity (Tratschin *et al.*, 1984; Laughlin *et al.*, 1986; Lebkowski *et*

29748-2

al., 1988; McLaughlin *et al.*, 1988). Details concerning the generation and use of rAAV vectors are described in U.S. Patents 5,139,941 and 4,797,368.

c. Retroviral Vectors

5 Retroviruses have promise as gene delivery vectors due to their ability to integrate their genes into the host genome, transferring a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and of being packaged in special cell-lines (Miller, 1992).

10 In order to construct a retroviral vector, a nucleic acid is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the *gag*, *pol*, and *env* genes but without the LTR and packaging components is constructed (Mann *et al.*, 1983). When a recombinant plasmid containing a cDNA, together with the retroviral LTR and packaging sequences is introduced into a special cell line (*e.g.*, by calcium phosphate precipitation for example), the
15 packaging sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann *et al.*, 1983). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad variety of cell types. However, integration and stable expression require the
20 division of host cells (Paskind *et al.*, 1975).

Lentiviruses are complex retroviruses, which, in addition to the common retroviral genes *gag*, *pol*, and *env*, contain other genes with regulatory or structural function. Lentiviral vectors are well known in the art (see, for example, Naldini *et al.*, 1996; Zufferey *et al.*, 1997; Blomer *et al.*, 1997; U.S. Patents 6,013,516 and 5,994,136). Some examples of lentivirus include the
25 Human Immunodeficiency Viruses: HIV-1, HIV-2 and the Simian Immunodeficiency Virus: SIV. Lentiviral vectors have been generated by multiply attenuating the HIV virulence genes, for example, the genes *env*, *vif*, *vpr*, *vpu* and *nef* are deleted making the vector biologically safe.

Recombinant lentiviral vectors are capable of infecting non-dividing cells and can be used for both *in vivo* and *ex vivo* gene transfer and expression of nucleic acid sequences. For
30 example, recombinant lentivirus capable of infecting a non-dividing cell wherein a suitable host cell is transfected with two or more vectors carrying the packaging functions, namely *gag*, *pol* and *env*, as well as *rev* and *tat* is described in U.S. Patent No. 5,994,136. One may target the recombinant virus by linkage of the envelope protein with an antibody or a particular ligand for targeting to a receptor of a particular cell-type. By inserting a

29748-2

sequence (including a regulatory region) of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target-specific.

5 d. Other Viral Vectors

Other viral vectors may be employed as vaccine constructs in the present invention. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988), sindbis virus, cytomegalovirus and herpes simplex virus may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; 10 Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988; Horwich *et al.*, 1990).

e. Delivery Using Modified Viruses

A nucleic acid to be delivered may be housed within an infective virus that has been engineered to express a specific binding ligand. The virus particle will thus bind specifically to 15 the cognate receptors of the target cell and deliver the contents to the cell. A novel approach designed to allow specific targeting of retrovirus vectors was developed based on the chemical modification of a retrovirus by the chemical addition of lactose residues to the viral envelope. This modification can permit the specific infection of hepatocytes *via* sialoglycoprotein receptors.

20 Another approach to targeting of recombinant retroviruses was designed in which biotinylated antibodies against a retroviral envelope protein and against a specific cell receptor were used. The antibodies were coupled *via* the biotin components by using streptavidin (Roux *et al.*, 1989). Using antibodies against major histocompatibility complex class I and class II antigens, they demonstrated the infection of a variety of human cells that bore those surface 25 antigens with an ecotropic virus *in vitro* (Roux *et al.*, 1989).

II. Vector Delivery and Cell Transformation

Suitable methods for nucleic acid delivery for transformation of an organelle, a cell, a tissue or an organism for use with the current invention are believed to include virtually any 30 method by which a nucleic acid (*e.g.*, DNA) can be introduced into an organelle, a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of DNA such as by *ex vivo* transfection (Wilson *et al.*, 1989, Nabel *et al.*, 1989), by injection (U.S. Patents 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859),

29748-2

including microinjection (Harlan and Weintraub, 1985; U.S. Patent No. 5,789,215); by electroporation (U.S. Patent No. 5,384,253; Tur-Kaspa *et al.*, 1986; Potter *et al.*, 1984); by calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990); by using DEAE-dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimer *et al.*, 1987); by liposome mediated transfection (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Nicolau *et al.*, 1987; Wong *et al.*, 1980; Kaneda *et al.*, 1989; Kato *et al.*, 1991) and receptor-mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988); by microprojectile bombardment (PCT Application Nos. WO 94/09699 and 95/06128; U.S. Patents 5,610,042; 5,322,783, 5,563,055, 5,550,318, 5,538,877 and 5,538,880); by agitation with silicon carbide fibers (Kaeppler *et al.*, 1990; U.S. Patents 5,302,523 and 5,464,765); by *Agrobacterium*-mediated transformation (U.S. Patents 5,591,616 and 5,563,055); by PEG-mediated transformation of protoplasts (Omirulleh *et al.*, 1993; U.S. Patents 4,684,611 and 4,952,500); by desiccation/inhibition-mediated DNA uptake (Potrykus *et al.*, 1985), and any combination of such methods. Through the application of techniques such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently transformed.

i. *Ex Vivo* Transformation

Methods for transfecting vascular cells and tissues removed from an organism in an *ex vivo* setting are known to those of skill in the art. For example, canine endothelial cells have been genetically altered by retroviral gene transfer in vitro and transplanted into a canine (Wilson *et al.*, 1989). In another example, yucatan minipig endothelial cells were transfected by retrovirus in vitro and transplanted into an artery using a double-balloon catheter (Nabel *et al.*, 1989). Thus, it is contemplated that cells or tissues may be removed and transfected *ex vivo* using the nucleic acids of the present invention. In particular aspects, the transplanted cells or tissues may be placed into an organism. In preferred facets, a nucleic acid is expressed in the transplanted cells or tissues.

ii. Injection

In certain embodiments, a nucleic acid may be delivered to an organelle, a cell, a tissue or an organism via one or more injections (*i.e.*, a needle injection), such as, for example, subcutaneously, intradermally, intramuscularly, intervenously, intraperitoneally, etc. Methods

29748-2

of injection of vaccines are well known to those of ordinary skill in the art (*e.g.*, injection of a composition comprising a saline solution). Further embodiments of the present invention include the introduction of a nucleic acid by direct microinjection. Direct microinjection has been used to introduce nucleic acid constructs into *Xenopus* oocytes (Harland and Weintraub, 5 1985).

iii. Electroporation

In certain embodiments of the present invention, a nucleic acid is introduced into an organelle, a cell, a tissue or an organism *via* electroporation. Electroporation involves the 10 exposure of a suspension of cells and DNA to a high-voltage electric discharge. In some variants of this method, certain cell wall-degrading enzymes, such as pectin-degrading enzymes, are employed to render the target recipient cells more susceptible to transformation by electroporation than untreated cells (U.S. Patent No. 5,384,253).

Alternatively, recipient cells can be made more susceptible to transformation by 15 mechanical wounding.

Transfection of eukaryotic cells using electroporation has been quite successful. Mouse pre-B lymphocytes have been transfected with human kappa-immunoglobulin genes (Potter *et al.*, 1984), and rat hepatocytes have been transfected with the chloramphenicol acetyltransferase gene (Tur-Kaspa *et al.*, 1986) in this manner. 20

iv. Calcium Phosphate

In other embodiments of the present invention, a nucleic acid is introduced to the cells using calcium phosphate precipitation. Human KB cells have been transfected with adenovirus 5 DNA (Graham and Van Der Eb, 1973) using this technique. Also in this manner, mouse L(A9), 25 mouse C127, CHO, CV-1, BHK, NIH3T3 and HeLa cells were transfected with a neomycin marker gene (Chen and Okayama, 1987), and rat hepatocytes were transfected with a variety of marker genes (Rippe *et al.*, 1990).

v. DEAE-Dextran

30 In another embodiment, a nucleic acid is delivered into a cell using DEAE-dextran followed by polyethylene glycol. In this manner, reporter plasmids were introduced into mouse myeloma and erythroleukemia cells (Gopal, 1985).

vi. Sonication Loading

Additional embodiments of the present invention include the introduction of a nucleic acid by direct sonic loading. LTK⁻ fibroblasts have been transfected with the thymidine kinase gene by sonication loading (Fechheimer *et al.*, 1987).

5

vii. Liposome-Mediated Transfection

In a further embodiment of the invention, a nucleic acid may be entrapped in a lipid complex such as, for example, a liposome. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Also contemplated is an nucleic acid complexed with Lipofectamine (Gibco BRL) or Superfect (Qiagen).

15 Liposome-mediated nucleic acid delivery and expression of foreign DNA *in vitro* has been very successful (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Nicolau *et al.*, 1987). The feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells has also been demonstrated (Wong *et al.*, 1980).

In certain embodiments of the invention, a liposome may be complexed with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda *et al.*, 1989). In other embodiments, a liposome may be complexed or employed in conjunction with nuclear non-histone chromosomal proteins (HMG-1) (Kato *et al.*, 1991). In yet further embodiments, a liposome may be complexed or employed in conjunction with both HVJ and HMG-1. In other
25 embodiments, a delivery vehicle may comprise a ligand and a liposome.

viii. Receptor Mediated Transfection

Still further, a nucleic acid may be delivered to a target cell via receptor-mediated delivery vehicles. These take advantage of the selective uptake of macromolecules by
30 receptor-mediated endocytosis that will be occurring in a target cell. In view of the cell type-specific distribution of various receptors, this delivery method adds another degree of specificity to the present invention.

Certain receptor-mediated gene targeting vehicles comprise a cell receptor-specific ligand and a nucleic acid-binding agent. Others comprise a cell receptor-specific ligand to which the

29748-2

nucleic acid to be delivered has been operatively attached. Several ligands have been used for receptor-mediated gene transfer (Wu and Wu, 1987; Wagner *et al.*, 1990; Perales *et al.*, 1994; Myers, EPO 0273085), which establishes the operability of the technique. Specific delivery in the context of another mammalian cell type has been described (Wu and Wu, 1993).

- 5 In certain aspects of the present invention, a ligand will be chosen to correspond to a receptor specifically expressed on the target cell population.

In other embodiments, a nucleic acid delivery vehicle component of a cell-specific nucleic acid targeting vehicle may comprise a specific binding ligand in combination with a liposome. The nucleic acid(s) to be delivered are housed within the liposome and the specific
10 binding ligand is functionally incorporated into the liposome membrane. The liposome will thus specifically bind to the receptor(s) of a target cell and deliver the contents to a cell. Such systems have been shown to be functional using systems in which, for example, epidermal growth factor (EGF) is used in the receptor-mediated delivery of a nucleic acid to cells that exhibit upregulation of the EGF receptor.

- 15 In still further embodiments, the nucleic acid delivery vehicle component of a targeted delivery vehicle may be a liposome itself, which will preferably comprise one or more lipids or glycoproteins that direct cell-specific binding. For example, lactosyl-ceramide, a galactose-terminal asialganglioside, have been incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes (Nicolau *et al.*, 1987). It is
20 contemplated that the tissue-specific transforming constructs of the present invention can be specifically delivered into a target cell in a similar manner.

E. Combined Administration of Therapeutic Genes and DNA Damaging Agents

I. Administration

- 25 Tumors that can be treated with the present invention include, but are not limited to, tumors of the brain (glioblastomas, medulloblastoma, astrocytoma, oligodendroglioma, ependymomas), lung, liver, spleen, kidney, lymph node, small intestine, pancreas, blood cells, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow, blood or other tissue. The tumor may be distinguished as metastatic and
30 non-metastatic. Various embodiments include tumor cells of the skin, muscle, fascia, brain, prostate, breast, endometrium, lung, head & neck, pancreas, small intestine, blood cells, liver, testes, ovaries, colon, skin, stomach, esophagus, spleen, lymph node, bone marrow or kidney. Other embodiments include fluid samples such as peripheral blood, lymph fluid, ascites, serous fluid, pleural effusion, sputum, cerebrospinal fluid, lacrimal fluid, stool or urine.

In accordance with the present invention, delivery of an Egr-1-driven expression vector and a DNA damaging agent is provided. This combination is capable of affecting a hyperproliferative disease (*e.g.*, cancer) in a subject, for example, by killing one or more target cells, inducing apoptosis in one or more target cells, reducing the growth rate of one or more target cells, reducing the incidence or number of metastases, reducing a tumor's size, inhibiting a tumor's growth, reducing the blood supply to a tumor or one or more target cells, promoting an immune response against one or more target cells or a tumor, preventing or inhibiting the progression of a cancer, or increasing the lifespan of a subject with a cancer.

More generally, the agents are provided in a combined amount with an effective dose to kill or inhibit proliferation of a cancer cell. This process may involve contacting the cell(s) with the agents at the same time or within a period of time wherein separate administration of the agents to a cell, tissue or organism produces a desired therapeutic benefit. This may be achieved by contacting the cell, tissue or organism with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two or more distinct compositions or formulations.

The terms "contacted" and "exposed," when applied to a cell, tissue or organism, are used herein to describe the process by which a therapeutic construct and DNA damaging agent are delivered to a target cell, tissue or organism or are placed in direct juxtaposition with the target cell, tissue or organism. To achieve cell killing or stasis, the agents are delivered to one or more cells in a combined amount effective to kill the cells or prevent them from dividing.

The expression construct may precede, be concurrent with and/or follow the DNA-damaging agent by intervals ranging from minutes to weeks. In embodiments where the agents are applied separately to a cell, tissue or organism, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the DNA damaging agent would still be able to induce expression from the the Egr-1 promoter in the cell, tissue or organism. For example, in such instances, it is contemplated that one may contact the cell, tissue or organism with the agents substantially simultaneously (*i.e.*, within less than about a minute). In other aspects, the agents may be administered about 1 minute, about 5 minutes, about 10 minutes, about 20 minutes about 30 minutes, about 45 minutes, about 60 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 32

WO 02/080849

PCT/US02/10733

hours, about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 37 hours, about 38 hours, about 39 hours, about 40 hours, about 41 hours, about 42 hours, about 43 hours, about 44 hours, about 45 hours, about 46 hours, about 47 hours, about 48 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 1, about 2, about 3, about 4, about 5, about 6, about 7 or about 8 weeks or more apart, and any range derivable therein.

Various combination may be employed. Non-limiting examples of such combinations are shown below, wherein an Egr-1 vector is "A" and a DNA damaging agent is "B":

A/B/A	B/A/B	B/B/A	A/A/B	A/B/B	B/A/A	A/B/B/B	B/A/B/B
B/B/B/A	B/B/A/B	A/A/B/B	A/B/A/B	A/B/B/A	B/B/A/A		
B/A/B/A	B/A/A/B	A/A/A/B	B/A/A/A	A/B/A/A	A/A/B/A		

Other combinations are also contemplated.

Administration of the agents of the present invention may follow general protocols for the administration of chemo- or gene therapeutics, taking into account the toxicity, if any. It is expected that the treatment cycles would be repeated as necessary. In particular embodiments, it is contemplated that various additional agents may be applied in any combination with the present invention.

"Effective amount" is defined as an amount of the agent that will decrease, reduce, inhibit or otherwise abrogate the growth of a cancer cell, induce apoptosis, inhibit metastasis, kill cells or induce cytotoxicity in cells.

The agents may, in general, be administered intravenously, intraarterially, intratumorally, parenterally or intraperitoneally. In particular, it is envisioned that local, regional and systemic delivery of the Egr-1 vector and DNA damaging agents to patients with cancers all will be suitable methods. A local administration also is useful, and includes direct injection of tumor mass, circumferential injection, and injections or bathing of a resected tumor bed. Regional delivery may include administration into the tumor vasculature or regional blood supply. Alternatively, systemic delivery of either or both DNA damaging agents and Egr-1 vector is appropriate in certain circumstances, for example, where extensive metastasis has occurred.

II. Formulations

The pharmaceutical forms of the agents are generally prepared for use as injectable solutions or dispersions. In all cases, the form should be sterile and must be fluid to the extent that easy syringability exists. It also should be stable under the conditions of manufacture and storage, and be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

F. Adjunct Therapies**I. Radiotherapeutic Agents**

Radiotherapeutic agents and factors include radiation and waves that induce DNA damage for example, γ -irradiation, X-rays, UV-irradiation, microwaves, electronic emissions, radioisotopes, and the like. Therapy may be achieved by irradiating the localized tumor site with the above described forms of radiations. It is most likely that all of these factors effect a broad range of damage DNA, on the precursors of DNA, the replication and repair of DNA, and the assembly and maintenance of chromosomes.

Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 weeks), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.

II. Surgery

Surgical treatment for removal of the cancerous growth is generally a standard procedure for the treatment of tumors and cancers. This attempts to remove the entire cancerous growth or to reduce it in order to make another therapy more effective, *e.g.*, combined with chemotherapy and/or radiotherapy to ensure the destruction of any remaining neoplastic or malignant cells. Thus, surgery may be used in combination with the present invention.

Approximately 60% of persons with cancer will undergo surgery of some type, which includes, for example, preventative, diagnostic or staging, curative and palliative surgery. Surgery, and in particular a curative surgery, may be used in conjunction with other therapies; such as the present invention and one or more other agents.

Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised and/or destroyed. It is further contemplated that surgery may remove, excise or destroy superficial cancers, precancers, or incidental amounts of normal tissue. Treatment by surgery includes for example, tumor resection, laser surgery, cryosurgery, electrosurgery, and microscopically controlled surgery (Mohs' surgery). Tumor resection refers to physical removal of at least part of a tumor. Upon excision of part of all of cancerous cells, tissue, or tumor, a cavity may be formed in the body.

Further treatment of the tumor or area of surgery may be accomplished treatment of the patient or surgical field with an additional anti-cancer therapy. Such treatment may be repeated, for example, about every 1, about every 2, about every 3, about every 4, about every 5, about every 6, or about every 7 days, or about every 1, about every 2, about every 3, about every 4, or

29748-2

about every 5 weeks or about every 1, about every 2, about every 3, about every 4, about every 5, about every 6, about every 7, about every 8, about every 9, about every 10, about every 11, or about every 12 months. These treatments may be of varying dosages as well.

5 III. Immune Therapy

An immunotherapeutic agent generally relies on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing. The antibody
10 also may be conjugated to a drug or toxin (*e.g.*, a chemotherapeutic, a radionuclide, a ricin A chain, a cholera toxin, a pertussis toxin, *etc.*) and serve merely as a targeting agent. Such antibody conjugates are called immunotoxins, and are well known in the art (see U.S. Patent 5,686,072, U.S. Patent 5,578,706, U.S. Patent 4,792,447, U.S. Patent 5,045,451, U.S. Patent 4,664,911, and U.S. Patent 5,767,072). Alternatively, the
15 effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.

In one aspect of immunotherapy, the tumor cell must bear some marker that is amenable to targeting, *i.e.*, is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present invention. Common tumor
20 markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, *erb B* and p155.

i. Immune Stimulators

25 In a specific aspect of immunotherapy is to use an immune stimulating molecule as an agent, or more preferably in conjunction with another agent, such as for example, a cytokines such as for example IL-2, IL-4, IL-12, GM-CSF, tumor necrosis factor; interferons alpha, beta, and gamma; F42K and other cytokine analogs; a chemokine such as for example MIP-1, MIP-1 β , MCP-1, RANTES, IL-8; or a growth factor such as for example FLT3 ligand.

30 One particular cytokine contemplated for use in the present invention is tumor necrosis factor. Tumor necrosis factor (TNF; Cachectin) is a glycoprotein that kills some kinds of cancer cells, activates cytokine production, activates macrophages and endothelial cells, promotes the production of collagen and collagenases, is an inflammatory mediator and also a mediator of septic shock, and promotes catabolism, fever and sleep. Some infectious agents cause tumor

regression through the stimulation of TNF production. TNF can be quite toxic when used alone in effective doses, so that the optimal regimens probably will use it in lower doses in combination with other drugs. Its immunosuppressive actions are potentiated by gamma-interferon, so that the combination potentially is dangerous. A hybrid of TNF and interferon- α also has been found to possess anti-cancer activity.

Another cytokine specifically contemplated is interferon alpha. Interferon alpha has been used in treatment of hairy cell leukemia, Kaposi's sarcoma, melanoma, carcinoid, renal cell cancer, ovary cancer, bladder cancer, non-Hodgkin's lymphomas, mycosis fungoides, multiple myeloma, and chronic granulocytic leukemia.

ii. Passive Immunotherapy

A number of different approaches for passive immunotherapy of cancer exist. They may be broadly categorized into the following: injection of antibodies alone; injection of antibodies coupled to toxins or chemotherapeutic agents; injection of antibodies coupled to radioactive isotopes; injection of anti-idiotypic antibodies; and finally, purging of tumor cells in bone marrow.

Preferably, human monoclonal antibodies are employed in passive immunotherapy, as they produce few or no side effects in the patient. However, their application is somewhat limited by their scarcity and have so far only been administered intralesionally. For example, human monoclonal antibodies to ganglioside antigens have been administered intralesionally to patients suffering from cutaneous recurrent melanoma (Irie & Morton, 1986). Regression was observed in six out of ten patients, following, daily or weekly, intralesional injections. In another study, moderate success was achieved from intralesional injections of two human monoclonal antibodies (Irie *et al.*, 1989).

It may be favorable to administer more than one monoclonal antibody directed against two different antigens or even antibodies with multiple antigen specificity. Treatment protocols also may include administration of lymphokines or other immune enhancers (Bajorin *et al.* 1988).

iii. Active Immunotherapy

In active immunotherapy, an antigenic peptide, polypeptide or protein, or an autologous or allogenic tumor cell composition or "vaccine" is administered, generally with a distinct bacterial adjuvant (Ravindranath & Morton, 1991; Morton & Ravindranath, 1996; Morton *et al.*, 1992; Mitchell *et al.*, 1990; Mitchell *et al.*, 1993). In melanoma immunotherapy, those patients

who elicit high IgM response often survive better than those who elicit no or low IgM antibodies (Morton *et al.*, 1992). IgM antibodies are often transient antibodies and the exception to the rule appears to be anti-ganglioside or anticarbohydrate antibodies.

iv. Adoptive Immunotherapy

In adoptive immunotherapy, the patient's circulating lymphocytes, or tumor infiltrated lymphocytes, are isolated *in vitro*, activated by lymphokines such as IL-2 or transduced with genes for tumor necrosis, and readministered (Rosenberg *et al.*, 1988; 1989). To achieve this, one would administer to an animal, or human patient, an immunologically effective amount of activated lymphocytes in combination with an adjuvant-incorporated anigenic peptide composition as described herein. The activated lymphocytes will most preferably be the patient's own cells that were earlier isolated from a blood or tumor sample and activated (or "expanded") *in vitro*. This form of immunotherapy has produced several cases of regression of melanoma and renal carcinoma, but the percentage of responders were few compared to those who did not respond.

G. Screening and Monitoring Effectiveness of Therapy

It is contemplated that in the context of the present invention one may remove cells, either tumor, normal or both tumor and normal cells, from an individual in order to either monitor the progress of treatment or as a part of the treatment. It is expected that one may monitor the effectiveness of treatment by removing such cells and treating such cells with DAPI staining to determine the level of chromatin condensation, measuring the level of apoptosis, measuring the level of neutral sphingomyelinase production or other methods such as the following.

One particular method for determining induction of apoptosis is terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labeling (TUNEL) assays, which measure the integrity of DNA (Gorczyca, 1993). This assay measures the fragmentation of DNA by monitoring the incorporation of labeled UTP into broken DNA strands by the enzyme terminal transferase. The incorporation can be monitored by electroscopy or by cell sorting methodologies (*e.g.*, FACS).

H. *Ex vivo* Delivery

In the present invention, it is contemplated that *ex vivo* gene therapy – isolation of cells from an animal or patient, treatment of the cells *in vitro*, and then the return of the modified cells

back into an animal or individual – may be employed. This approach permits higher doses of therapy, and the addition of other factors that are may not be possible in an *in vivo* setting. In particular, autologous bone marrow cell (BMC) transplantation is used as a salvage procedure in which blood or bone marrow is taken and stored prior to an intensification of radiation or chemotherapy. Treatment of such cells to prevent reintroduction of cancer cells is highly beneficial.

In preparing human mononuclear cells (MNC), an aliquot of marrow is layered into a receptacle such as a centrifuge tube. Initially, MNC may be obtained from a source of bone marrow, *e.g.*, tibiae, femora, spine, ribs, hips, sternum, as well as the humeri, radi, ulna, tibiae, and fibulae. Additionally, these cells also can be obtained from cord blood, peripheral blood, or cytokine-mobilized peripheral blood. Other sources of human hematopoietic stem cells include embryonic yolk sac, fetal liver, fetal and adult spleen, and blood. The marrow layer is centrifuged to produce a pellet of red cells at the bottom of the tube, a clear layer of media, an interface layer which contains the MNC and a plasma medium layer on top. The interface layer may then be removed using, for example, suction. Centrifugation of this layer at 1000g ultimately yields a MNC pellet. This pellet may then be resuspended in a suitable buffer for cell sorting by FACS. The isolated MNC are cloned *in vitro* to expand the of immunologically active cells. The expanded, therapeutically active cells are then provided to the patient to obtain a therapeutic effect.

I. Clinical Trials

This example is concerned with the development of human treatment protocols by methods comprising: a) providing an expression construct comprising a nucleic acid segment encoding a cancer therapeutic protein, the nucleic acid segment being positioned under the control of an Egr-1 promoter; and b) administering the expression construct to a human subject in combination with a DNA damaging compound that can induce free radicals. The methods may further comprise administering to the patient other cancer therapeutic compounds, ionizing radiation and/or any other adjunct cancer therapy. These methods will be of use in the clinical treatment of various cancers/tumors and diseases in which transformed or cancerous cells play a role. Such treatment will be particularly useful tools in anti-tumor therapy, for example, in treating patients with lung cancer, prostate cancer, ovarian cancer, testicular cancer, brain cancer, skin cancer, colon cancer, gastric cancer, esophageal cancer, tracheal cancer, head & neck cancer, pancreatic cancer, liver cancer, breast cancer, ovarian cancer, lymphoid cancer, leukemia, cervical cancer, or vulvar cancer.

28778-148

The free radical-inducing DNA damaging compound may be a platinum compound such as cisplatin, a nitrogen mustard, cytoxan, cyclophosphamide, mitomycin c, adriamycin, iphosphamide, bleomycin, doxorubicin, procarbazine, actinomycin, chlorambucil, carboplatinum, busulfan, bcnu, ccnu, hexamethylmelamineoxaliplatin, epirubicin, daunorubicin, 5 camptothecin, or mitoxantrone. Any protein with anti-cancer properties may be used and examples of such compounds are described elsewhere in the specification.

The various elements of conducting a clinical trial, including patient treatment and monitoring, are known to those of skill in the art in light of the present disclosure. The following information is being presented as a general guideline for use in establishing clinical trials using 10 the methods of the invention.

Candidates for the phase 1 clinical trial will be patients on which all conventional therapies have failed. The therapeutic formulations of the invention will be administered on a tentative weekly basis. Effectiveness of the therapy and disease course can be assessed by monitoring parameters such as tumor size, presence of tumor markers, and/or bone marrow 15 infiltration of cancer cells on a periodic basis. Tests that will be used to monitor the progress of the patients and the effectiveness of the treatments include: physical exam, X-ray, blood work and other clinical laboratory methodologies. In addition, peripheral blood and bone marrow samples will be drawn to assess the expression of the anticancer protein expressed by the vector. The doses given in the phase 1 study will be escalated as is done in standard phase 1 clinical 20 phase trials, *i.e.*, doses will be escalated until maximal tolerable ranges are reached.

Clinical responses may be defined by acceptable measure. For example, a complete response may be defined by complete disappearance of evidence of cancer cells for at least 2 months. Whereas a partial response may be defined by a 50% reduction of cancer cells for at least 2 months.

25 The typical course of treatment will vary depending upon the individual patient and disease being treated in ways known to those of skill in the art. A typical treatment course may comprise about six doses delivered over a 7 to 21 day period. Upon election by the clinician the regimen may be continued with six doses every three weeks or on a less frequent (monthly, bimonthly, quarterly etc.) basis. For example, a patient with lung cancer might be treated in 30 eight week cycles, although longer duration may be used if no adverse effects are observed with the patient, and shorter terms of treatment may result if the patient does not tolerate the treatment as hoped. Each cycle will consist of between 20 and 35 individual doses spaced equally, although this too may be varied depending on the clinical situation. Of course, these are only

exemplary times for treatment, and the skilled practitioner will readily recognize that many other time-courses are possible.

Patients may, but need not, have received previous or concurrent surgical, chemo-, radio- or gene therapeutic treatments. Optimally the patient will exhibit adequate bone marrow
5 function (defined as peripheral absolute granulocyte count of $> 2,000/\text{mm}^3$ and platelet count of $100,000/\text{mm}^3$, adequate liver function (bilirubin 1.5mg/dl) and adequate renal function (creatinine 1.5mg/dl).

The therapeutic compositions of the present invention will typically be administered parenterally in dosage unit formulations containing standard, well known non-toxic
10 physiologically acceptable carriers, adjuvants, and vehicles as desired. The term parenteral as used herein includes intravenous, introtumoral, subcutaneous, intramuscular, intra, or infusion techniques. These compositions will be provided in an amount effective to kill or inhibit the proliferation of the cell.

Regional delivery of the compositions are an efficient method for delivering a
15 therapeutically effective dose to counteract the clinical disease. Alternatively, systemic delivery may be appropriate. The therapeutic compositions of the present invention may be administered to the patient directly at the site of the tumor. The volume of the composition should usually be sufficient to ensure that the entire surface of the tumor is contacted by the therapeutic composition. In one embodiment, administration simply entails injection of the therapeutic
20 composition into the tumor. In another embodiment, a catheter is inserted into the site of the tumor and the cavity may be continuously perfused for a desired period of time.

Of course, the above-described treatment regimes may be altered in accordance with the knowledge gained from pre-clinical trials. Those of skill in the art will be able to take the information disclosed in this specification and optimize treatment regimes.

25

J. Examples

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the
30 examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

35

EXAMPLE 1**Methods**

Cells and cell culture. Cell lines Seg-1, a human esophageal adenocarcinoma (Dr. David Beer, University of Michigan, Ann Arbor, MI) and DHD/K12/TRb (PROb), a rat colon adenocarcinoma established in syngeneic BD-IX rats by 1,2-dimethylhydrazine induction (Dr. Francois Martin, University of Dijon, France) were maintained in Dulbecco's Modified Eagle Medium (DMEM) (GibcoBRL, Grand Island, NY) supplemented with Fetal Bovine Serum (FBS, 10% v/v) (Intergen, Purchase, NY), penicillin (100 IU/ml), and streptomycin (100 µg/ml) (GibcoBRL), at 37°C and 7.5% CO₂.

Animals. Athymic nude mice (Frederick Cancer Research Institute, Frederick, MD) received food and water *ad libitum*. Experiments were in accordance with the guidelines of the University of Chicago.

Viral vectors. The viral vectors Ad.Egr.TNF.11D and Ad.Null.3511.11D (GenVec, Gaithersburg, MD) were stored at -80°C, and diluted to the appropriate concentration in formulation buffer.

***In vitro* measurement of TNF-α protein.** Seg-1 and PROb cells were plated at 10⁵ cells/well in 12-well plates (Becton Dickinson, Bedford, MA), grown overnight, and infected with either Ad.Null.3511.11D or Ad.Egr.TNF.11D at 100 multiplicities of infection (MOI) in serum-free medium for 2-3 hours. IR treated cells in complete medium were exposed to 5 Gy using a Pantak PCM 1000 x-ray generator. Cells in the cisplatin group were exposed to 5 µM cisplatin in complete medium. Cells and supernatants were harvested by scraping at 24, 48, and 72 hours, and production of human TNF-α was quantified by ELISA (R&D Systems, Minneapolis, MN) following three cycles of freeze-thaw lysis. Assays were performed in triplicate. Duplicate treatment plates were used to adjust for the cytotoxicity of IR and cisplatin. Cells were harvested using versene (0.02% EDTA in HBSS) and trypsin-EDTA (0.25% trypsin, 1 mM EDTA·4Na) (GibcoBRL) and cells were counted using the hemocytometer with trypan blue (0.4%) exclusion (GibcoBRL). Protein assays were performed to normalize for protein concentration (Bio-Rad, Hercules, CA).

***In vitro* luciferase reporter assay.** The Egr-1 constructs pE425 (596 base pairs containing all CArG elements, no AP-1 sites) and pE660 (the minimal Egr-1 promoter, 115 base pairs no CArG elements) (Datta *et al.*, 1993) were evaluated following sequence confirmation and insertion of the PCR product into the pGL3 basic firefly luciferase reporter plasmid construct (Promega, Madison, WI) by enzyme restriction and ligation. JM109 competent cells

(Stratagene, La Jolla, CA) were transformed with these plasmids, endotoxin-free maxipreps (Qiagen, Valencia, CA) were prepared, and product confirmation was performed by PCR, sequencing, enzyme restriction, and gel electrophoresis. Seg-1 and PROb cells were plated at 10^5 cells/well in 12-well plates and transfected with the firefly luciferase reporter plasmid constructs, pGL3 basic (promoterless, negative control), pGL3 660 (minimal Egr-1 promoter), or pGL3 425 (Egr-1 promoter containing all CArG elements) using the TransFast transfection reagent (Promega). All groups were co-transfected with the Renilla luciferase reporter plasmid construct pRL-TK (HSV thymidine kinase promoter) to normalize for transfection efficiency. 48 hr later, cells were exposed to IR (20Gy) or cisplatin (5 μ M). Cells were harvested 6 hr later, and luciferase activity was measured using the Dual-Luciferase reporter assay system (Promega).

***In vivo* measurement of TNF- α protein.** Seg-1 or PROb cells ($5 \times 10^6/0.1$ ml) were injected in the right hind limb of nude mice. Tumor bearing mice were randomized to one of 4 groups: intratumoral (IT) Ad.Null.3511.11D (2×10^8 p.u./10 μ l) with intraperitoneal (IP) with normal saline (NS) or cisplatin (8 mg/kg) and IT Ad.Egr.TNF.11D (2×10^8 p.u./10 μ l) with IP NS or cisplatin. IP NS or cisplatin treatments were administered after IT vector. Two consecutive IT and IP injections were given. Animals were euthanized, and xenografts were harvested 48 hours following the second IP injection. Xenografts were snap frozen in liquid nitrogen, and homogenized in RIPA buffer (NaCl 150 mM, Tris 10 mM, pH 7.5, EDTA 5 mM, pH 7.5, PMSF 100 mM, Leupeptin 1 μ g/ml, Aprotinin 2 μ g/ml) using a Brinkman Polytron Homogenizer (Kinematica AG, Lucerne, Switzerland). Following three freeze-thaw lysis cycles, the homogenate was centrifuged at 10,000 rpm (Sorvall RC5C SS34 rotor) for 10 minutes, 4°C. TNF- α levels in the supernatants were measured using ELISA and protein assays were performed (Bio-Rad, Hercules, CA).

***In vivo* regrowth studies.** Seg-1 or PROb cells ($5 \times 10^6/0.1$ ml) were injected in the right hind limb of nude mice. Tumor bearing mice were assigned to one of 4 groups: intratumoral (IT) Ad.Null.3511.11D (2×10^8 p.u./10 μ l) with intraperitoneal (IP) normal saline (NS) or cisplatin (3 mg/kg) and IT Ad.Egr.TNF.11D (2×10^8 p.u./10 μ l) with IP NS or cisplatin. IP NS or cisplatin injections were given following the IT vector injection, and 4 consecutive daily IT and IP injections were given. Xenografts were measured every 2 days using calipers and tumor volume was calculated (length x width x thickness)/2. Fractional tumor volumes (V/V_0 , V_0 = day 0 volume) were calculated and plotted.

Statistical analysis. Statistical significance was determined using two-tail student's *t*-test.

EXAMPLE 2***In vitro* Induction of TNF- α in Human and Rat Tumor Cells Following Infection with Ad.Egr.TNF.11D and Exposure to Cisplatin**

5

Because Egr-1 is induced through the CArG elements of its promoter by ROIs and/or DNA damage, TNF- α production by tumor cells infected with an adenoviral vector in which CArG elements are upstream to a TNF- α cDNA (Ad.Egr.TNF.11D) was analyzed after exposure to cisplatin, a DNA damaging agent that alters cellular redox status (Davis *et al.*, 2001). TNF- α production was tested in human esophageal Seg-1 cells and rat colorectal PROb cells following exposure to 5 μ M cisplatin. TNF- α concentrations were determined using an ELISA that is specific for human TNF- α . No TNF- α protein was detectable in Seg-1 cell pellets or supernatants from cultures infected with the null vector (Ad.Null.3511.11D), and treated with IR or cisplatin. In contrast, significant levels of TNF- α protein were detected in cultures of Seg-1 cells infected with the Ad.Egr.TNF.11D vector and exposed to IR (5 Gy) at 24, 48 and 72 hrs (768.8 $\pm$ 32.6, 593.0 $\pm$ 27.6, 746.0 $\pm$ 18.5, respectively) compared cells infected with vector alone (269.3 $\pm$ 1.9, 167.8 $\pm$ 8.4, 260.6 $\pm$ 14.9; P < 0.001). Combined treatment with Ad.Egr.TNF.11D + IR resulted in a 2.9, 3.5 and 2.9-fold increase in TNF production. A similar induction of TNF- α protein was detected in Seg-1 cells infected with the Ad.Egr.TNF.11D vector and exposed to 5 μ M cisplatin compared with vector alone at 24 hrs (885.3 $\pm$ 28.7), 48 hrs (892.6 $\pm$ 21.3) and 72 hrs (901.7 $\pm$ 21.7; P < 0.001, FIG. 5A). Combined treatment with Ad.Egr.TNF.11D + cisplatin thus resulted in a 3.3, 5.3 and 3.5-fold increase in TNF production.

Comparable experiments were conducted with PROb cell cultures. Again no TNF- α protein was detectable in PROb cell pellets or supernatants from cultures infected with the null vector (Ad.Null.3511.11D) and treated with IR or cisplatin. Significant levels of TNF- α protein were detected in cultures of PROb cells infected with the Ad.Egr.TNF.11D vector and exposed to IR (5 Gy) at 24, 48 and 72 hrs (55.1 $\pm$ 4.6, 440.5 $\pm$ 7.0, 812.7 $\pm$ 8.9, respectively) compared cells infected with vector alone (17.9 $\pm$ 1.7, 169.7 $\pm$ 5.2, 522.5 $\pm$ 11.3; P < 0.001). Combined treatment with Ad.Egr.TNF.11D + IR resulted in a 3.1, 2.6 and 1.6-fold increase in TNF production. A similar induction of TNF- α protein was detected in Seg-1 cells infected with the Ad.Egr.TNF.11D vector and exposed to 5 μ M cisplatin compared with vector alone at 24, 48 and 72 hrs (52.4 $\pm$ 0.6, 318.6 $\pm$ 30.6, 812.2 $\pm$ 11.0; P < 0.001, FIG. 5B). Combined treatment with Ad.Egr.TNF.11D + cisplatin resulted in a 2.9, 1.9 and 1.6-fold increase in TNF production.

30

These findings from the Seg-1 and PROb cell lines demonstrate that IR and cisplatin induce TNF- α expression by activating the Egr-1 promoter.

With a selective tumor-targeting vector, a cisplatin inducible genetic construct enhances the effects of cisplatin, in this case by TNF- α . Cisplatin and TNF- α have different mechanisms of cell killing and therefore, cells resistant to cisplatin may be sensitive to TNF- α and vice versa. Also, necrosis is induced by high intratumoral concentrations of TNF- α by damage to the tumor microvasculature, which may be useful in treatment of TNF- α and cisplatin resistant tumors. The cisplatin/Ad.Egr.TNF .11D strategy thus is an effective therapy for localized tumors not effectively treated with radiotherapy or surgery. Also, Ad.Egr.TNF.11D may enhance the local effects of combination chemo-radiation therapy.

EXAMPLE 3

CAR_G Elements of the Egr-1 Promoter Mediate Induction of TNF- α by Cisplatin

To study whether the CAR_G elements of the Egr-1 promoter are inducible by cisplatin, Egr-1 promoter activity was assessed by measuring activation of the luciferase reporter gene in Seg-1 and PROb cells co-transfected with the firefly luciferase reporter plasmid constructs pGL3 basic (negative control), pGL3 660 (consisting only of the minimal Egr-1 promoter, no CAR_G elements), or pGL3 425 (consisting of all the CAR_G elements, no AP-1 sites), and the Renilla luciferase reporter plasmid construct pRL-TK. Minimal luciferase activity (LA) was detectable in Seg-1 cells transfected with the pGL3 basic plasmid construct (LA = 0.01 – 0.02) or with the pGL3 660 plasmid construct (LA = 0.10-0.18). However, Seg-1 cells transfected with the pGL3 425 plasmid construct exhibited a 2.4-fold increase ($P=0.005$) in relative luciferase activity (LA = 15.07) following exposure to IR (20 Gy) compared to untreated control (LA = 6.37) and a 2.0-fold increase ($P=0.005$) in luciferase activity (LA = 2.89) following exposure to cisplatin (50 μ M) compared with untreated control (FIG. 6A).

Similar results were obtained with the PROb cell line. Minimal luciferase activity was detectable in PROb cells transfected with the pGL3 basic plasmid construct (LA = 0.21 – 0.30) or with the pGL3 660 plasmid construct (LA = 0.76 – 1.84). PROb cells transfected with the pGL3 425 plasmid construct exhibited a 4.2-fold increase ($P=0.004$) in luciferase activity (LA = 57.75) following exposure to IR (20 Gy) compared to untreated control (LA = 13.69) and a 3.6-fold increase ($P=0.01$) in luciferase activity (LA = 49.40) following exposure to cisplatin (50 μ M) compared with untreated control (FIG. 6B). These data demonstrate that CAR_G elements of

the Egr-1 promoter are inducible by cisplatin and mediate the transcriptional activation of the chimeric Egr-1.TNF- α gene.

EXAMPLE 4

Induction of TNF- α in Human and Rat Tumor Xenografts Following Treatment With Ad.Egr.TNF.11D and Cisplatin

TNF- α induction by cisplatin was analyzed following infection of human and rodent tumors with the Ad.Egr.TNF.11D vector. Xenografts of Seg-1 or PROb cells growing the hind limbs of athymic nude mice were injected intratumorally (IT) with Ad.Null.3511.11D or Ad.Egr.TNF.11D. Tumor bearing mice were injected IP with either normal saline (NS) or cisplatin (3 mg/kg). TNF- α concentration in tumor homogenates was quantified using ELISA.

No TNF- α protein was detected in Seg-1 tumor homogenates following injection of the Ad.Null.3511.11D vector and systemic treatment with either NS or cisplatin. A significant increase (3.5-fold) in intratumoral TNF- α protein was observed following combined treatment with Ad.Egr.TNF.11D + cisplatin (1294.0 ± 438.5 pg/mg) compared with treatment with vector alone (366.5 ± 52.6 pg/mg; $P < 0.05$, FIG. 7A).

No TNF- α protein was detected in PROb tumor homogenates following injection of Ad.Null.3511.11D vector and systemic treatment with either NS or cisplatin. However, a significant increase (2.7-fold) in intratumoral TNF- α protein was observed following combined treatment with Ad.Egr.TNF.11D + cisplatin (878.6 ± 61.9 pg/mg) compared to treatment with vector alone (321.4 ± 27.7 pg/mg; $P < 0.001$, FIG. 7B). These findings demonstrate *in vivo* induction of TNF- α protein by cisplatin and verify that the TNF- α protein is a product of the Ad.Egr.TNF.11D vector rather than the tumor tissue.

EXAMPLE 5

Cisplatin Inducible Ad.Egr.TNF.11D Enhances Treatment of Human and Rat Xenografts

Potential antitumor effects of chemo-inducible Ad.Egr.TNF.11D and cisplatin were examined in Seg-1 and PROb xenografts. In the Seg-1 studies, mean tumor volume on day 0 (initiation of treatment) was 381.3 ± 10.8 mm³ (n = 48, 12 mice per treatment group). Xenografts were injected IT with either Ad.Null.3511.11D or Ad.Egr.TNF.11D. Mice were injected IP with either NS or cisplatin. Control tumors (Ad.Null.3511.11D + NS) doubled in size

by day 4 and exhibited a 4.7 fold increase in mean tumor volume by day 14. A similar growth pattern was observed in tumors treated with the Ad.Egr.TNF.11D vector + NS (2.0-fold increase at day 4 and 3.8-fold increase in mean volume at day 14). Significant tumor regression was observed in the tumors receiving combined treatment with Ad.Egr.TNF.11D + cisplatin compared with tumors treated with the null vector + cisplatin on days 4 ($P=0.045$), 6 ($P<0.005$), 8 ($P<0.002$), 10 ($P<0.001$), 12 ($P<0.004$), and 14 ($P<0.021$), (FIG. 8A).

In the PROb studies, mean tumor volume on day 0 was $244.2 \pm 6.2 \text{ mm}^3$ ($n = 40$, 10 mice per treatment group). Control tumors (Ad.Null.3511.11D + NS) grew steadily doubling in size by day 4, exhibiting a 4.4 fold increase in mean tumor volume by day 14. A similar growth pattern was observed for tumors treated with the Ad.Egr.TNF.11D vector + NS (1.6-fold increase at day 4 and 3.6-fold increase in mean volume at day 14). Significant tumor regression was observed in the tumors receiving combined treatment with Ad.Egr.TNF.11D + cisplatin compared with tumors treated with the null vector + cisplatin on days 4 ($P=0.045$), 6 ($P<0.001$), 8 ($P=0.048$), 10 ($P<0.001$), 12 ($P<0.001$), and 14 ($P=0.002$), (FIG. 8B). Taken together, these data support an antitumor interaction between cisplatin and Ad.Egr.TNF.11D in xenografts of human and rodent origin. These findings are consistent with, and supported by, TNF- α induction by cisplatin observed in the *in vitro* and *in vivo* experiments. Although toxicity was observed following treatment with cisplatin, no additional toxicity was observed following combined treatment with cisplatin and Ad.Egr.TNF.11D.

Thus, cisplatin, a commonly employed chemotherapeutic agent which stimulates ROI production, induces the production of TNF- α in human and rodent cancer cells infected with an adenoviral vector encoding the CArG elements of the Egr-1 promoter ligated upstream to a cDNA encoding TNF- α . Significant antitumor effects of both TNF- α and cisplatin were observed in both experimental tumor systems. Thus, the present invention provides a new approach that combines the use of chemotherapeutic agents, such as cisplatin, with the temporal and spatial control of gene therapy using antitumor genes.

For most common human neoplasms, grossly visible tumors are not effectively treated with most standard chemotherapeutic agents. The transcriptional targeting strategy such as the Egr1-TNF- α and cisplatin is useful when it is possible to infuse or directly inject gross tumors, even in the presence of micrometastases, since the vector/cisplatin combination is effective against gross tumor and cisplatin against micrometastatic disease. The direct injection of tumors should be improved with the recent advances in radiographic imaging analysis of tumor, e.g. PET scans, combined with CT image reconstruction. Additionally, recent developments in the

targeting of viral vectors to tumors may provide additional specificity to chemoinducible gene therapy of metastatic cancer.

5 All of the compositions and methods disclosed and claimed herein can be made and
executed without undue experimentation in light of the present disclosure. While the
compositions and methods of this invention have been described in terms of preferred
embodiments, it will be apparent to those of skill in the art that variations may be applied to the
compositions and methods and in the steps or in the sequence of steps of the method described
10 herein without departing from the concept, spirit and scope of the invention. More specifically,
it will be apparent that certain agents which are both chemically and physiologically related may
be substituted for the agents described herein while the same or similar results would be
achieved. All such similar substitutes and modifications apparent to those skilled in the art are
deemed to be within the spirit, scope and concept of the invention as defined by the appended
15 claims.

29748-2

J. References

The following references are listed, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein.

- 5 U. S. Patent 4,664,911
- U. S. Patent 4,684,611
- U. S. Patent 4,792,447
- U.S. Patent 4,797,368
- U. S. Patent 4,952,500
- 10 U. S. Patent 5,045,451
- U. S. Patent 5,139,941
- U. S. Patent 5,302,523
- U. S. Patent 5,322,783
- U. S. Patent 5,354,855
- 15 U. S. Patent 5,359,046
- U. S. Patent 5,384,253
- U. S. Patent 5,464,765
- U. S. Patent 5,538,877
- U. S. Patent 5,538,880
- 20 U. S. Patent 5,550,318
- U. S. Patent 5,563,055
- U. S. Patent 5,578,706
- U. S. Patent 5,580,859
- U. S. Patent 5,589,466
- 25 U. S. Patent 5,591,616
- U. S. Patent 5,610,042
- U. S. Patent 5,656,610
- U. S. Patent 5,686,072
- U. S. Patent 5,702,932
- 30 U. S. Patent 5,736,524
- U. S. Patent 5,767,072
- U. S. Patent 5,780,448
- U. S. Patent 5,925,565
- U. S. Patent 5,935,819

U. S. Patent 5,945,100,

U. S. Patent 5,981,274

U. S. Patent 5,994,136

U. S. Patent 5,994,624

5 U. S. Patent 6,013,516

Arap *et al.*, *Cancer Res.*, 55:1351-1354, 1995.

Ausubel *et al.*, In: *Current Protocols in Molecular Biology*, John, Wiley and Sons, Inc., 1994.

10 Baichwal and Sugden, In: *Gene Transfer*, Kucherlapati R, ed., New York, Plenum Press, pp. 117-148, 1986.

Bajorin *et al.*, *Proc. Annu. Meet. Am. Soc. Clin. Oncol.*, 7:A967, 1988.

Bedzyk *et al.*, *J. Biol. Chem.*, 265:18615, 1990

Blomer *et al.*, *J Virol.* 71(9): 6641-6649, 1997

Bonavida *et al.*, *Gynecol Oncol*, 38:333-9, 1990.

15 Burbage *et al.*, *Leuk Res*, 21(7):681-690, 1997.

Bussemakers *et al.*, *Cancer Res.*, 52:2916-2922, 1992.

Caldas *et al.*, *Nat. Genet.*, 8:27-32, 1994.

Carbonelli *et al.* *FEMS Microbiol Lett.* 177(1):75-82, 1999.

Casey *et al.*, *Oncogene*, 6:1791-1797, 1991.

20 Chandler *et al.*, *Proc Natl Acad Sci USA*, 94(8):3596-3601, 1997.

Chaudhary *et al.* *Proc. Natl. Acad. Sci.*, 87:9491, 1990

Chen and Okayama, *Mol. Cell Biol.*, 7:2745-2752, 1987.

Cheng *et al.*, *Cancer Res.*, 54:5547-5551, 1994.

Cheung *et al.*, *Arch Biochem Biophys*, 305(2):563-569, 1993.

25 Cocea, *Biotechniques*, 23:814-816, 1997.

Cotten *et al.*, *Proc Natl Acad Sci USA*, 89(13):6094-6098, 1992.

Coupar *et al.*, *Gene*, 68:1-10, 1988.

Curiel, In: *Viruses in Human Gene Therapy*, J.-M.H. Vos (Ed.), Carolina Academic Press, Durham, NC, pp 179-212, 1994.

30 Datta *et al.*, *Proc Natl Acad Sci USA*, 90:2419-22, 1993.

Davis *et al.*, *J Pharmacol Exp Ther*, 296:1-6, 2001.

Demetri *et al.*, *J Clin Oncol*, 7:1545-53, 1989.

Duan *et al.*, *J Neurooncol*, 52:23-36, 2001.

Edelman and Crossin, *Annu. Rev. Biochem.*, 60:155-190, 1991.

- Edelman, *Annu. Rev. Biochem.*, 54:135-169, 1985.
- Fechheimer *et al.*, *Proc. Natl. Acad. Sci. USA*, 84:8463-8467, 1987.
- Fiers, *FEBS Letters*, 285(2):199-212, 1991.
- Forster and Symons, *Cell*, 49:211-220, 1987.
- 5 Fraley *et al.*, *Proc. Natl. Acad. Sci. USA*, 76:3348-3352, 1979.
- Friedmann, *Science*, 244:1275-1281, 1989.
- Frixen *et al.*, *J. Cell Biol.*, 113:173-185, 1991.
- Gerlach *et al.*, *Nature (London)*, 328:802-805, 1987
- Ghosh and Bachhawat, *In: Liver diseases, targeted diagnosis and therapy using specific receptors*
 10 *and ligands*, (Wu G, Wu C ed.), New York: Marcel Dekker, pp. 87-104, 1991.
- Giancotti and Ruoslahti, *Cell*, 60:849-859, 1990.
- Gonzalez-Zulueta *et al.*, *Cancer Research*, 55(20):4531-4535, 1995.
- Goodbourn and Maniatis, *Proc. Natl. Acad. Sci. USA*, 85:1447, 1988.
- Gopal, *Mol. Cell Biol.*, 5:1188-1190, 1985.
- 15 Gorczyca *et al.*, *Cancer Res.*, 53:1945-1951, 1993.
- Graham and Van Der Eb, *Virology*, 52:456-467, 1973.
- Grunhaus and Horwitz, *Seminar in Virology*, 3:237-252, 1992.
- Hall, *Radiobiology for the Radiologist*, Harper and Row, 1988.
- Hall, *Radiobiology for the Radiologist*, Harper and Row, 1994.
- 20 Harland and Weintraub, *J. Cell Biol.*, 101:1094-1099, 1985.
- Havell *et al.*, *J Exp Med*, 167:1067-85, 1988.
- Herman *et al.*, *Cancer Research*, 55(20):4525-4530, 1995.
- Hollstein *et al.*, *Science*, 253:49-53, 1991.
- Horwich *et al.* *J. Virol.*, 64:642-650, 1990.
- 25 Hussussian *et al.*, *Nature Genetics*, 15-21, 1994.
- Inouye *et al.*, *Nucl. Acids Res.*, 13:3101-3109, 1985.
- Irie and Morton, *Proc. Nat'l Acad. Sci. USA* 83:8694-8698, 1986
- Johnson and Stevenson, *In: Cancer.Principles and Practice of Oncology* (ed. DeVita, V.T.,
 Hellman and Rosenberg,) 376-88, 2001.
- 30 Joyce, *Nature*, 338:217-244, 1989.
- Kamb *et al.*, *Nature Genetics*, 8:22-26, 1994.
- Kamb *et al.*, *Science*, 2674:436-440, 1994.
- Kaneda *et al.*, *Science*, 243:375-378, 1989.
- Kartalou and Essigmann, *Mutat Res*, 478:23-43, 2001.

- Kato *et al.*, *J. Biol. Chem.*, 266:3361-3364, 1991.
- Kelleher and Vos, *Biotechniques*, 17(6):1110-1117, 1994.
- Kim and Cook, *Proc. Natl. Acad. Sci. USA*, 84:8788-8792, 1987.
- Kucuk *et al.*, *Am J Clin Oncol*, 23:371-5, 2000.
- 5 Levenson *et al.*, *Human Gene Therapy*, 9:1233-1236, 1998.
- Lebkowski *et al.*, *Mol Cell Biol*, 8(10):3988-3996, 1988.
- Lidor *et al.*, *Am J Obstet Gynecol*;177(3):579-585, 1997.
- Lin and Guidotti, *J. Biol. Chem.*, 264:14408-14414, 1989.
- Laughlin *et al.*, *J. Virol.*, 60(2):515-524, 1986.
- 10 McLaughlin *et al.*, *J. Virol.*, 62(6):1963-1973, 1988.
- Macejak and Sarnow, *Nature*, 353:90-94, 1991.
- Mann *et al.*, *Cell*, 33:153-159, 1983.
- Massuda *et al.*, *Proc Natl Acad Sci U S A*, 94(26):14701-14706, 1997.
- Matsura *et al.*, *Brit. J. Cancer*, 66:1122-1130, 1992.
- 15 Mauceri *et al.*, *Int J Cancer*, 97:410-5, 2002.
- Merlo *et al.*, *Nat Med.*, (7):633-4, 1995.
- Michel and Westhof, *J. Mol. Biol.*, 216:585-610, 1990.
- Miksicek *et al.*, *Cell*, 46:203, 1986.
- Mizukami *et al.*, *Virology*, 217:124-130, 1996.
- 20 Mori *et al.*, *Cancer Res.*, 54:3396-3397, 1994.
- Morton and Ravindranath, In *Tumor Immunology*, Dalglish (ed.), London: Cambridge University Press, 1-55, 1996.
- Morton *et al.*, *Ann. Surg.*, 216:463-482, 1992.
- Muzyczka, *Curr. Top. Microbiol. Immunol.*, 158:97-129, 1992.
- 25 Myers, EPO 0273085.
- Nabel *et al.*, *Science*, 244:1342-1344, 1989.
- Nakamoto *et al.*, *Anticancer Res*, 20:4087-96, 2000.
- Naldini *et al.*, *Science*, 272(5259):195, 1996
- Nicolas and Rubenstein, In: *Vectors: A survey of molecular cloning vectors and their uses*,
 30 Rodriguez and Denhardt (eds.), Stoneham: Butterworth, pp. 493-513, 1988.
- Nicolau and Sene, *Biochim. Biophys. Acta*, 721:185-190, 1982.
- Nicolau *et al.*, *Methods Enzymol.*, 149:157-176, 1987.
- Nobri *et al.*, *Nature*, 368:753-756, 1995.
- Obrador *et al.*, *Curr Pharm Biotechnol*, 2:119-30, 2001.

- Obrink, *BioEssays*, 13:227-233, 1991.
- Odin and Obrink, *Exp. Cell Res.*, 171:1-15, 1987.
- Okamoto *et al.*, *Proc. Nat'l Acad. Sci. USA*, 91:11045-11049, 1994.
- Old, *Science*, 230:630-2, 1985.
- 5 Omirulleh *et al.*, *Plant Mol. Biol.*, 21:415-28, 1993.
- Orlow *et al.*, *Cancer Res.*, 54:2848-2851, 1994.
- Paskind *et al.*, *Virology*, 67:242-248, 1975.
- PCT 94/09699
- PCT 95/06128
- 10 Pelletier and Sonenberg, *Nature*, 334:320-325, 1988.
- Perales *et al.*, *Proc. Natl. Acad. Sci.* 91:4086-4090, 1994.
- Potrykus *et al.*, *Mol. Gen. Genet.*, 199:183-188, 1985.
- Potter *et al.*, *Proc. Nat'l Acad. Sci. USA*, 81:7161-7165, 1984.
- Ravindranath and Morton, *Intern. Rev. Immunol.*, 7: 303-329, 1991.
- 15 Reinhold-Hurek and Shub, *Nature*, 357:173-176, 1992.
- Remington's Pharmaceutical Sciences, 15th ed., pp. 1035-1038 and 1570-1580.
- Ridgeway, In: *Vectors: A survey of molecular cloning vectors and their uses*, Rodriguez RL, Denhardt DT, ed., Stoneham:Butterworth, pp. 467-492, 1988.
- Rippe *et al.*, *Mol. Cell Biol.*, 10:689-695, 1990.
- 20 Robaye *et al.*, *Am J Pathol*, 138:447-53, 1991.
- Rosenberg, P., *Autotransfusion (editorial)" Duodecim.*, 106 (14) p1027-9, 1990.
- Roux *et al.*, *Proc. Natl Acad. Sci. USA*, 86:9079-9083, 1989.
- Sarver *et al.*, *Science*, 247:1222-1225, 1990.
- Scanlon *et al.*, *Proc Natl Acad Sci USA*, 88:10591-10595, 1991.
- 25 Serrano *et al.*, *Nature*, 366:704-707, 1993.
- Serrano *et al.*, *Science*, 267:249-252, 1995.
- Slungaard *et al.*, *J Exp Med*, 171:2025-41, 1990.
- Smith and Rutledge, *Natl Cancer Inst Monogr*, 42:169-172, 1975.
- Spriggs *et al.*, *J Natl Cancer Inst*, 80:1039-44, 1988.
- 30 Staba *et al.*, *Gene Therapy*, 5:293-300, 1998.
- Takahashi *et al.*, *Cancer Res.*, 52:734-736, 1992.
- Tartaglia *et al.*, *Cell*, 74:845-53, 1993.
- Temin, In: *Gene Transfer*, Kucherlapati (ed.), New York: Plenum Press, pp. 149-188, 1986.
- Thom *et al.*, *J Clin Oncol*, 13:264-73, 1995.

- Tratschin *et al.*, *Mol. Cell. Biol.*, 4:2072-2081, 1984.
- Tur-Kaspa *et al.*, *Mol. Cell Biol.*, 6:716-718, 1986.
- Umbas *et al.*, *Cancer Res.*, 52:5104-5109, 1992.
- Wagner *et al.*, *Proc. Natl. Acad. Sci.* 87(9):3410-3414, 1990.
- 5 Watanabe *et al.*, *Cancer Res*, 48:2179-83, 1988.
- Weichselbaum *et al.*, *Acta Oncol* 40, 735-8, 2001.
- Weichselbaum *et al.*, *Int J Radiat Oncol Biol Phys*, 30:229-34, 1994.
- Weinberg, *Science*, 254:1138-1145, 1991.
- Wilson *et al.*, *Science*, 244:1344-1346, 1989.
- 10 Wong *et al.*, *Gene*, 10:87-94, 1980.
- Wu and Wu, *Adv. Drug Delivery Rev.*, 12:159-167, 1993.
- Wu and Wu, *Biochem.*, 27:887-892, 1988.
- Wu and Wu, *J. Biol. Chem.*, 262:4429-4432, 1987.
- Young *et al.*, *N Engl J Med.* 7:299(23):1261-1266, 1978.
- 15 Zufferey *et al.*, *Biotechnol*, 15(9):871-875, 1997

31802-1

CLAIMS:

1. An in vitro or ex vivo method for expressing a protein of interest comprising:

(a) providing an expression construct comprising a nucleic acid segment encoding said protein of interest, said nucleic acid segment being positioned under the control of an early growth response factor 1 (Egr-1) promoter;

(b) transferring said expression construct into a cell;

(c) contacting said cell with at least one DNA damaging chemotherapeutic agent, wherein said DNA damaging chemotherapeutic agent induces expression of said protein of interest from said Egr-1 promoter.

2. The method of claim 1, wherein said chemotherapeutic agent is cisplatin, nitrogen mustard, cytoxan, cyclophosphamide, mitomycin c, adriamycin, iphosphamide, bleomycin, doxorubicin, procarbazine, actinomycin, chlorambucil, carboplatinum, busulfan, bcnu, ccnu, hexamethylmelamineoxaliplatin, epirubicin, daunorubicin, camptothecin, or mitoxantrone.

3. The method of claim 1, wherein said chemotherapeutic agent is cyclophosphamide.

4. The method of claim 1, wherein said chemotherapeutic agent is doxorubicin.

5. The method of claim 1, wherein said chemotherapeutic agent is cisplatin.

6. The method of any one of claims 1 to 5, wherein step (c) comprises contacting said cell with at least a second DNA damaging chemotherapeutic agent.

31802-1

7. The method of any one of claims 1 to 6, further comprising contacting said cell with ionizing radiation.

8. The method of any one of claims 1 to 7, wherein said cell is a cancer cell.

5 9. The method of claim 8, wherein said cancer cell is a lung cancer cell, prostate cancer cell, ovarian cancer cell, testicular cancer cell, brain cancer cell, skin cancer cell, colon cancer cell, gastric cancer cell, esophageal cancer cell, tracheal cancer cell, head and neck cancer cell, pancreatic
10 cancer cell, liver cancer cell, breast cancer cell, ovarian cancer cell, lymphoid cancer cell, leukemia cell, cervical cancer cell, or vulvar cancer cell.

10. The method of any one of claims 1 to 9, wherein said expression construct further comprises an origin of
15 replication.

11. The method of any one of claims 1 to 10, wherein said expression construct further comprises a selectable marker.

12. The method of any one of claims 1 to 11, wherein said expression construct further comprises a polyadenylation signal
20 operably linked to said nucleic segment.

13. The method of any one of claims 1 to 12, wherein said expression construct is a plasmid.

14. The method of any one of claims 1 to 12, wherein said expression construct is a viral vector.

25 15. The method of claim 14, wherein said viral vector is an adenoviral vector, an adeno-associated viral vector, a retroviral vector, a vaccinia viral vector, or a herpesviral vector.

31802-1

16. The method of claim 14 or 15, wherein said viral vector is lacking one or more viral genes, thus rendering said viral vector non-replicative.

17. The method of any one of claims 1 to 16, wherein said
5 protein of interest is a tumor suppressor, an inducer of apoptosis, an enzyme, a cytokine, or a toxin.

18. The method of claim 17, wherein said tumor suppressor is Rb, p16, p53, PTEN, MDA7, BRCA1 or BRCA2.

19. The method of claim 17, wherein said inducer of apoptosis
10 is Bax, Bad, Bik, AdE1B, Bim, Bcl-X_s, Bak, TRAIL, Harakiri or Bid.

20. The method of claim 17, wherein said enzyme is thymidine kinase, cytosine deaminase, or hypoxanthine guanine phosphoribosyl transferase.

15 21. The method of claim 17, wherein said cytokine is TNF- α .

22. The method of claim 17, wherein said toxin is pseudomonas exotoxin, diptheria toxin, cholera toxin, pertussis toxin A subunit, enterotoxin A, or ricin A chain.

23. The method of any one of claims 1 to 22, wherein said cell
20 is a human cell.

24. Use, in the manufacture of a medicament for treating cancer in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent,

wherein the expression construct comprises a nucleic acid
25 segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early growth response factor 1 (Egr-1) promoter; and

31802-1

wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

25. Use, for treating cancer in a subject, of an expression
5 construct in combination with a DNA damaging chemotherapeutic agent,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early
10 growth response factor 1 (Egr-1) promoter; and

wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

26. The use of claim 24 or 25, wherein said expression
15 construct is formulated for local or regional delivery to a tumor located in said subject.

27. The use of claim 24 or 25, wherein said expression construct is formulated for systemical delivery.

28. The use of claim 24 or 25, wherein said expression
20 construct is formulated for delivery via intratumoral injection or by direct injection into tumor vasculature.

29. The use of any one of claims 24 to 28, wherein said DNA damaging chemotherapeutic agent is formulated for administration prior to said expression construct.

25 30. The use of any one of claims 24 to 28, wherein said DNA damaging chemotherapeutic agent is formulated for administration after said expression construct.

31802-1

31. The use of any one of claims 24 to 28, wherein said DNA damaging chemotherapeutic agent is formulated for administration at the same time as said expression construct.

32. The use of any one of claims 24 to 31, wherein said
5 expression construct is formulated for administration in at least two doses.

33. The use of any one of claims 24 to 32, wherein said DNA damaging chemotherapeutic agent is formulated for administration in at least two doses.

10 34. The use of any one of claims 24 to 33, wherein said cancer therapeutic protein is a tumor suppressor, an inducer of apoptosis, an enzyme, or a toxin.

35. Use, in the manufacture of a medicament for inhibiting tumor cell growth in a subject, of an expression construct in
15 combination with a DNA damaging chemotherapeutic agent,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an Egr-1 promoter; and

20 wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

36. Use, for inhibiting tumor cell growth in a subject, of an expression construct in combination with a DNA damaging
25 chemotherapeutic agent,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic

31802-1

acid segment being positioned under the control of an early growth response factor 1 (Egr-1) promoter; and

wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

37. The use of claim 35, wherein said medicament is adapted for administration in combination with an ionizing radiation treatment.

38. The use of claim 36, in combination with an ionizing radiation treatment.

39. The use of any one of claims 35 to 38, wherein the cancer therapeutic protein is TNF- α .

40. The use of any one of claims 35 to 39, wherein the DNA damaging chemotherapeutic agent is cisplatin.

41. The use of any one of claims 35 to 39, wherein said DNA damaging chemotherapeutic agent is cyclophosphamide.

42. The use of any one of claims 35 to 39, wherein said DNA damaging chemotherapeutic agent is doxorubicin.

43. The use of any one of claims 35 to 42, wherein said expression construct and said DNA damaging chemotherapeutic agent are formulated for administration to a tumor cell in said subject.

44. The use of any one of claims 35 to 42, wherein said expression construct and said DNA damaging chemotherapeutic agent are formulated for administration to the vasculature of a tumor in said subject.

31802-1

45. Use, in the manufacture of a medicament for killing a tumor cell in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early growth response factor 1 (Egr-1) promoter; and

wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

46. Use, for killing a tumor cell in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an Egr-1 promoter; and

wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

47. The use of claim 45, wherein said medicament is adapted for administration in combination with an ionizing radiation treatment.

48. The use of claim 46, in combination with an ionizing radiation treatment.

49. The use of any one of claims 45 to 48, wherein said DNA damaging chemotherapeutic agent is cyclophosphamide.

31802-1

50. The use of any one of claims 45 to 48, wherein said DNA damaging chemotherapeutic agent is doxorubicin.

51. The use of any one of claims 45 to 50, wherein said expression construct and said DNA damaging chemotherapeutic agent are formulated for administration to a tumor cell in said subject.

52. The use of any one of claims 45 to 50, wherein said expression construct and said DNA damaging chemotherapeutic agent are formulated for administration to the vasculature of a tumor in said subject.

53. The use of any one of claims 45 to 52, wherein said cancer therapeutic protein is TNF- α .

54. Use, in the manufacture of a medicament for inhibiting tumor cell metastasis in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent, wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early growth response factor 1 (Egr-1) promoter; and wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

55. Use, for inhibiting tumor cell metastasis in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic

31802-1

acid segment being positioned under the control of an early response growth factor 1 (Egr-1) promoter; and

wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

56. Use, in the manufacture of a medicament for reducing tumor burden in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early response growth factor 1 (Egr-1) promoter; and

wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

57. Use, for reducing tumor burden in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic compound,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early response growth factor 1 (Egr-1) promoter; and

wherein said DNA damaging chemotherapeutic compound induces expression of said cancer therapeutic protein from said Egr-1 promoter.

58. Use, in the manufacture of a medicament for rendering a tumor operable, of an expression construct in combination with a DNA damaging chemotherapeutic agent,

31802-1

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early response growth factor 1 (Egr-1) promoter; and

5 wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

59. Use, for rendering a tumor operable, of an expression construct in combination with a DNA damaging chemotherapeutic
10 agent,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an early response growth factor 1 (Egr-1) promoter; and

15 wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

60. An in vitro or ex vivo method for expressing a protein of interest comprising:

20 (a) providing a cell comprising an expression construct comprising a nucleic acid segment encoding said protein of interest, said nucleic acid segment being positioned under the control of an early response growth factor 1 (Egr-1) promoter; and

25 (b) contacting said cell with a DNA damaging chemotherapeutic agent which induces expression of said protein of interest from said Egr-1 promoter.

31802-1

61. The method of claim 60, wherein the DNA damaging chemotherapeutic agent is 5-fluorouracil (5-FU), gemcitabine, cyclophosphamide, doxorubicin, or paclitaxel.

62. The method of claim 60 or 61, wherein the protein of
5 interest is TNF- α .

63. The method of any one of claims 60 to 62, wherein the cell is a tumor cell.

64. The method of any one of claims 60 to 63, wherein the method further comprises contacting the cell with ionizing
10 radiation.

65. Use, in the manufacture of a medicament for inhibiting tumor cell growth in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent that induces an early growth response factor 1 (Egr-1) promoter,
15 wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic acid segment being positioned under the control of an Egr-1 promoter; and

wherein said DNA damaging chemotherapeutic agent induces
20 expression of said cancer therapeutic protein from said Egr-1 promoter.

66. Use, for inhibiting tumor cell growth in a subject, of an expression construct in combination with a DNA damaging chemotherapeutic agent that induces an early growth response
25 factor 1 (Egr-1) promoter,

wherein the expression construct comprises a nucleic acid segment encoding a cancer therapeutic protein, said nucleic

31802-1

acid segment being positioned under the control of the Egr-1 promoter; and

wherein said DNA damaging chemotherapeutic agent induces expression of said cancer therapeutic protein from said Egr-1 promoter.

67. The use of claim 66, in combination with an ionizing radiation treatment.

68. The use of claim 65, wherein said medicament is adapted for administration in combination with an ionizing radiation treatment.

69. The use of any one of claims 65 to 68, wherein the DNA damaging chemotherapeutic agent is 5-fluorouracil (5-FU), gemcitabine, cyclophosphamide, doxorubicin, or paclitaxel.

70. The use of any one of claims 65 to 69, wherein said cancer therapeutic protein is TNF- α .

71. The use of any one of claims 65 to 70, wherein said expression construct and said DNA damaging chemotherapeutic agent are formulated for administration to a tumor cell in said subject.

72. The use of any one of claims 65 to 70, wherein said expression construct and said DNA damaging chemotherapeutic agent are formulated for administration to the vasculature of a tumor in said subject.

73. An expression vector in combination with at least one DNA damaging chemotherapeutic agent for use in therapy, wherein the expression vector comprises a nucleic acid segment encoding a protein of interest, the nucleic acid segment being positioned under the control of an early growth response factor

31802-1

1 (Egr-1) promoter, wherein said at least one DNA damaging
chemotherapeutic agent induces expression of said protein of
interest from said Egr-1 promoter in a cell.

74. The method of claim 1, wherein said DNA damaging
5 chemotherapeutic agent is 5-fluorouracil (5-FU).

75. The method of claim 1, wherein said DNA damaging
chemotherapeutic agent is hydroxyurea.

76. The method of claim 1, wherein said DNA damaging
chemotherapeutic agent is capecitabine.

10 77. The use of any one of claims 35 to 39, wherein said DNA
damaging chemotherapeutic agent is 5-fluorouracil (5-FU).

78. The use of any one of claims 35 to 39, wherein said DNA
damaging chemotherapeutic agent is hydroxyurea.

79. The use of any one of claims 35 to 39, wherein said DNA
15 damaging chemotherapeutic agent is capecitabine.

80. The method of claim 60, wherein said DNA damaging
chemotherapeutic agent is 5-fluorouracil (5-FU).

81. The method of claim 60, wherein said DNA damaging
chemotherapeutic agent is hydroxyurea.

20 82. The method of claim 60, wherein said DNA damaging
chemotherapeutic agent is capecitabine.

83. The use of any one of claims 65 to 68, wherein said DNA
damaging chemotherapeutic agent is 5-fluorouracil (5-FU).

84. The use of any one of claims 65 to 68, wherein said DNA
25 damaging chemotherapeutic agent is hydroxyurea.

31802-1

85. The use of any one of claims 65 to 68, wherein said DNA damaging chemotherapeutic agent is capecitabine.

86. The vector of claim 73, wherein said DNA damaging chemotherapeutic agent is 5-fluorouracil (5-FU).

5 87. The vector of claim 73, wherein said DNA damaging chemotherapeutic agent is hydroxyurea.

88. The vector of claim 73, wherein said DNA damaging chemotherapeutic agent is capecitabine.




FIG. 1




FIG.2




FIG. 3




FIG. 4




FIG. 5A







FIG. 5B

**FIG. 6A**

**FIG. 6B**

**FIG. 7A**




FIG. 7B




FIG. 8A




FIG. 8B

